perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

FUS Mislocalization Rewires a Cortical Gene Network to Drive Cognitive and Behavioral Impairment in ALS

2
3

15

16

1

Raphaelle CASSEL¹, Félicie LORENC¹, Aurélie BOMBARDIER¹, Claudia DE TAPIA¹,
Stéphane DIETERLE¹, Cláudio GOUVEIA ROQUE², Christopher A. JACKSON², Geoffrey
STUART-LOPEZ¹, Caroline ROUAUX¹, Simon J. GUILLOT¹, Marie-Christine BIRLING³,
Pascal KESSLER⁴, Maurizio GRASSANO⁵, Bryan TRAYNOR^{6,7,8,9}, Adriano CHIO⁵, Raju
ROY¹⁰, James SHORTER¹⁰, Fergal M. WALDRON¹¹, Jenna M. GREGORY¹¹, Hemali
PHATNANI^{2,12}, Luc DUPUIS^{1,13*}, Salim MEGAT^{1,13**}

- 121Université de Strasbourg, Inserm, Strasbourg Translational Neuroscience and13Psychiatry, UMR-S1329, Centre de Recherches en Biomédecine; Strasbourg,14France
 - 2 Center for Genomics of Neurodegenerative Disease, New York Genome Center, 101 Avenue of the Americas, New York, NY 10013, USA
- 17 3 PHENOMIN-Institut Clinique de la Souris, Université de Strasbourg, Illkirch,
 18 France
- 194Université de Strasbourg, INSERM, UMS 38, Imaging Core Facility PIC-STRA,20CRBS, Strasbourg, France.
- 215ALS Center "Rita Levi Montalcini" Department of Neuroscience, University of Turin,22Turin, Italy.
- A Neuromuscular Diseases Research Section, National Institute on Aging (NIA),
 National Institutes of Health (NIH), Bethesda, MD 20892, USA.
- 25
 7 Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
- 27 8 NINDS, NIH, Bethesda, MD 20892, USA.
- ASO Therapeutics Laboratory, National Center for Advancing Translational
 Sciences, NIH, Rockville, MD 20850, USA.
- 3010Department of Biochemistry and Biophysics, Perelman School of Medicine,
University of Pennsylvania, Philadelphia, PA 19104. U.S.A.
- 32 11 Institute of Medical Sciences, University of Aberdeen, UK.
- Department of Neurology, Center for Translational and Computational
 Neuroimmunology, Columbia University, New York, NY 10032, USA
- 36 13 Equal contribution.
- 37 * correspondence: <u>ldupuis@unistra.fr</u>
- 38 ** correspondence: <u>salim.megat@inserm.fr</u> 39
- 40 Lead contact: Luc DUPUIS, Idupuis@unistra.fr
- 41 42

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Summary 43

- 44 (149 words)
- 45

46 Cognitive and behavioral impairment affects up to half of individuals with amyotrophic lateral 47 sclerosis (ALS), but their molecular origin remains unresolved. Here, we identify 48 mislocalization of the RNA-binding protein FUS in cortical neurons as a defining feature in ALS 49 patients with cognitive impairment (ALS-ci). Selective mislocalization of FUS in adult cortical 50 projection neurons in mice is sufficient to trigger ALS-ci- and ALS with behavioral impairment 51 (ALS-bi)-like phenotypes, including deficits in sociability, and neurodegeneration. Single-52 nucleus transcriptomics reveal a conserved FUS-dependent gene network downregulated in 53 these mice and ALS-ci patients. This regulon is enriched for ALS genetic risk factors and newly 54 implicates FBXO16 in ALS-bi. Carriers of protein-truncating FBXO16 variants display 55 behavioral abnormalities, frontotemporal atrophy, and increased levels of dementia-linked 56 biomarkers. These findings define a neuron-intrinsic mechanism for cognitive and behavioral 57 dysfunction in ALS and nominate FUS mislocalization and its downstream gene network as 58 therapeutic targets.

59

Keywords 60

61 Amyotrophic lateral sclerosis, fronto-temporal dementia, cognitive impairment, behavioral

- 62 impairment, mouse models, genetics, single cell biology.
- 63

Graphical abstract 64





66 67

69

70

71

72

73

74

75

76

77

78

68 Highlights

- Transcriptional fingerprint of FUS mislocalization is observed in cortical projection neurons of ALS patients
- FUS mislocalization leads to downregulation in cortical projection neurons of a crossspecies conserved regulon shared with TDP43
- FUS mislocalization in adult cortical projection neurons is sufficient to trigger ALS related cognitive and behavioral impairment in mouse models
- FUS is mislocalized and the FUS regulon is downregulated in ALS patients with • cognitive impairment
- The FUS regulon is enriched in genetic risk factors for cognitive and behavioral • impairment in ALS
- 79 Carriers of protein truncating variants of FBXO16, one of the FUS regulon genes, 80 display behavioral, imaging and biochemical markers of ALS with behavioral 81 impairment.

Introduction 82

83

84 Amyotrophic lateral sclerosis (ALS) is the most frequent adult-onset disease of motor neurons. 85 ALS is characterized by the onset of motor symptoms in the 5th or 6th decade of life, rapidly progressing to fatal paralysis, usually within two to three years after symptoms' onset. A 86 87 substantial fraction of ALS patients (up to 50%) develop additional symptoms, unrelated to the 88 motor system, in particular variable cognitive impairment (ALS-ci) or behavioral impairment 89 (ALS-bi), with some patients even presenting with frontotemporal dementia (ALS-FTD) 90 (Abrahams, 2023). The relevance of this ALS-FTD clinical continuum is substantiated by the 91 existence of a common pathology between ALS and FTD, in particular aggregates of TDP-43, 92 an RNA-binding protein (RBP), as well as common genetic associations (Goutman et al., 93 2022a, b). It remains unclear, however, whether ALS-ci, ALS-bi and ALS without cognitive 94 impairment have distinct mechanisms. Indeed, TDP-43 pathology in areas involved in 95 cognition, behavior and executive functions is a poor predictor of ALS-ci or ALS-bi (Bampton 96 et al., 2024; Rifai et al., 2024; Suzuki et al., 2024), suggesting that additional pathways 97 contribute to the development of these extra-motor deficits.

98

99 An attractive hypothesis would be that other, yet undetermined, pathological features develop in ALS-ci or ALS-bi patients but not in patients without cognitive or behavioral impairment, to 100 101 cause the ci/bi phenotypes. As a matter of fact, the co-occurrence of several proteinopathies 102 is frequent in neurodegenerative diseases, and is generally associated with worsened 103 prognosis (Irwin et al., 2017; James et al., 2016; Karanth et al., 2020; Katsumata et al., 2020; 104 Robinson et al., 2023). Interestingly, the heritability of ALS is enriched in TDP-43 targets 105 (Brown et al., 2022; Ling et al., 2015; Ma et al., 2022; Megat et al., 2023). Beyond TDP-43, the 106 heritability of ALS is also enriched in targets of another RBP linked to ALS, FUS (Megat et al., 107 2023). Mutations in the FUS gene cause severe familial ALS cases through altered nuclear 108 import of the FUS protein (Kwiatkowski et al., 2009: Moens et al., 2025: Scekic-Zahirovic et 109 al., 2017; Scekic-Zahirovic et al., 2016; Vance et al., 2009). FUS aggregates are also observed 110 in a subset of FTD cases, in complex aggregates that also include TAF15 and other RBPs 111 (Mackenzie et al., 2011a; Mackenzie et al., 2011b; Neumann et al., 2011; Urwin et al., 2010). 112 Importantly, FUS is also mislocalized in the cytoplasm of neurons in sporadic ALS, even in the 113 absence of obvious FUS aggregates (Tyzack et al., 2019; Tyzack et al., 2021), as well as in 114 C9ORF72 ALS (Rifai et al., 2022). Despite these observations, the distribution of FUS 115 mislocalization across ALS, ALS-ci and ALS-bi patients remains unknown, and the 116 consequences of FUS mislocalization on ALS clinical features, including cognitive and 117 behavioral, are poorly characterized.

118

119 Here, we demonstrate that FUS mislocalization in cortical neurons is more pronounced in ALS-120 ci than in ALS patients. Furthermore, FUS mislocalization in adult projection neurons is 121 sufficient to lead to ALS-ci/bi-like phenotypes in mice. Through integration of various single-122 cell datasets, we identify a gene module downstream of FUS mislocalization that is 123 downregulated in cortical neurons of ALS-ci patients and identify genetic associations between 124 FBXO16 and WWOX, two genes of this module, with ALS-bi and ALS-ci respectively. Thus, 125 FUS mislocalization in projection neurons compromises expression of a gene network 126 underlying the risk of cognitive and behavioral impairment in ALS.

- 127
- 128

129 Results

130

131 Mislocalization of FUS is sufficient to recapitulate transcriptomic alterations in ALS 132 excitatory projection neurons

133 Previous studies have observed mislocalization of FUS in neurons of sporadic and familial ALS 134 patients, including C9ORF72 (Rifai et al., 2022; Tyzack et al., 2019; Tyzack et al., 2021), but 135 did not define downstream transcriptional consequences. To identify those alterations, we 136 generated a single-nuclei RNA sequencing (snRNAseg) dataset of the frontal cortex of 137 Fus^{ΔNLS/+} mice. This mouse model is a knock-in mouse model expressing a FUS protein 138 truncated of its C-terminal nuclear localization sequence (NLS). This leads to the cytoplasmic 139 accumulation of FUS (Scekic-Zahirovic et al., 2017; Scekic-Zahirovic et al., 2016), without 140 aggregation. Similar mutations have been documented in ALS patients, and the cytoplasmic 141 accumulation of FUS without aggregation is similar to what has been reported in ALS patients 142 (Rifai et al., 2022; Tyzack et al., 2019; Tyzack et al., 2021). We used this novel dataset as a 143 blueprint of FUS mislocalization and compared it with a publicly available dataset of motor 144 cortex of ALS patients (Pineda et al., 2024) (Figure 1A-B). Single nuclei RNA sequencing of 145 frontal cortex of Fus^{ANLS/+} mice yielded 78,514 nuclei allowing the identification of 21 clusters 146 that reflect large cellular subtypes as previously described in the mouse primary motor cortex 147 (Network, 2021). Analysis of human snRNAseq from the motor cortex yielded 156,545 nuclei split across 19 subclasses that allow the identification of the major cellular subtypes such as 148 149 upper and deep layer excitatory neurons, interneurons derived from the medial and caudal 150 ganglionic eminences, as well as different types of non-neuronal cells such as microglia, 151 astrocytes and endothelial cells (Figure 1C-D). Principal component analysis of Fus^{ΔNLS/+} mice 152 and ALS patients showed strong transcriptional differences among excitatory projection 153 neurons that is confirmed with a higher number of differentially expressed (DE) genes 154 compared to inhibitory neurons and non-neuronal cells (Figure 1C-D). Gene ontology analysis performed on the overlapped DE genes in excitatory neurons in Fus^{ΔNLS/+} mice and ALS 155 156 patients show a similar enrichment in terms associated with mitochondrial function, RNA 157 binding and mRNA translation (FDR<0.05) suggesting a common underlying mechanism 158 driving neurodegeneration in human ALS patient and Fus^{ΔNLS/+} mice. These results show that 159 endogenous mislocalization of FUS leads to similar transcriptional alterations as ALS 160 specifically in cortical projection neurons (CPNs) (Figure 1E-F).

161

162 A conserved FUS regulon shared with TDP-43 in ALS-vulnerable neurons

163 FUS is an RNA binding protein with a prion-like domain and thousands of RNA targets (Lagier-164 Tourenne et al., 2012; Rogelj et al., 2012). To narrow down to the critical RNA targets 165 associated with ALS, we reasoned that the genes of interest should (i) be modulated by FUS 166 in CPNs and (ii) show similar alterations in mouse models and ALS patients. To integrate gene 167 expression changes in a systems-level framework, we performed a co-expression analysis 168 across available mouse and human datasets to identify significant co-expressed modules, 169 using single-cell transcriptome of human L5 extra-telencephalic (L5-ET) vulnerable neurons 170 (Pineda et al., 2024) and single-nuclei transcriptome of Fus^{ANLS/+} mice (Figure 2A-B). We 171 identified a total of 4 gene modules with signed correlation to ALS in either L5-ET human 172 neurons, or *Fus*^{ΔNLS/+} transcriptome, or both. Only one module, color coded "Turquoise". 173 showed correlation to ALS in both mouse and human species (Figure 2B-E). Specifically, the 174 "Turquoise" module was downregulated in both human and mouse datasets (FDR <0.05) 175 (Figure 2E). As we assume the module to be regulated through a FUS-dependent mechanism. 176 we decided to name this module "FUS regulon" (Table S1). Gene ontology of the FUS regulon 177 showed enrichment in genes involved in functions altered in ALS, e.g. cilium organization (De 178 Decker et al., 2025), cytoskeleton or RNA binding (Brown and Al-Chalabi, 2017) (FDR<0.05) 179 (Figure 2F). Downregulation of the FUS regulon was widespread across CPN in Fus^{ΔNLS/+} mice 180 as shown in Figure 2G using eigengene of the FUS regulon as a global measurement of FUS

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

181 regulon expression. For instance, the FUS regulon was downregulated in L5-PT neurons 182 (grouping most extra-telencephalic neurons in mice) (unadjusted-p = 0.040), but also in L5-IT 183 (intra-telencephalic neurons) (*Bonferroni corrected-p <0.05) in Fus^{ΔNLS/+} mice (Figure 2G). 184 Downregulation of the FUS regulon was significant in L5-ET neurons of the motor cortex of 185 sporadic ALS patients (*Bonferroni corrected-p <0.05) (Figure 2H). To determine the 186 specificity of the FUS regulon towards FUS among other RBPs, we evaluated expression of 187 the FUS regulon in a publicly available dataset (Van Nostrand et al., 2020) that explored 188 transcriptional effects of downregulation of 217 RBPs (Figure 2I). In this dataset, FUS ranked 189 8th in RBPs downregulating the FUS regulon (**Table S2**). Interestingly, TDP-43 ranked 2nd as 190 RBP with the most downregulation of the FUS regulon, suggesting that FUS and TDP-43 are 191 both necessary for strong expression of the FUS regulon. Consistent with this, knockdown of 192 TDP-43 in iPSC-derived motor neurons (Brown et al., 2022) led to decreased expression of 193 the FUS regulon (**p<0.01) (Figure 2J), and expression of the FUS regulon was decreased in 194 TDP-43 negative neuronal nuclei as compared to TDP-43 positive nuclei in FTD-TDP43 195 patients samples (***p<0.001) (Liu et al., 2019) (Figure 2K). These results demonstrate that 196 FUS mislocalization leads to downregulation of the FUS regulon in CPNs, phenocopying 197 transcriptional alterations in vulnerable neurons in patients and is associated with FUS and 198 TDP43 loss of function.

199

Adult-onset FUS mislocalization in mouse cortical projection neurons reproduces

molecular, pathological and electrical alterations of ALS patients As the transcriptional consequences of FUS mislocalization were most prominent in CPNs, we then sought to restrict FUS mislocalization in adult excitatory projection neurons in a mouse

204 model. Thus, we generated a novel mouse Fus allele allowing conditional ablation of the 205 nuclear localization signal (NLS), leading to cytoplasmic accumulation of FUS. We engineered 206 the Fus locus to insert loxP sequences in intron 12 and downstream of exon 15 (Figure S1A). 207 The second loxP site is followed by a cDNA encoding exons 13 and 14 of Fus, followed by 3 208 transcriptional stop cassettes and a poly-adenylation signal to restore exons 13 and 14 after 209 CRE recombination (Figure S1A). Thus, CRE-mediated recombination is expected to delete 210 exon 15 leading to a FUS protein without NLS, and thus to the same mutant FUS protein as in 211 constitutive Fus ANLS/+ mice. Germ line transmission of the recombinant allele was obtained and 212 mice heterozygous and homozygous for the targeted allele will hereafter be referred to as 213 Fus^{exon15}. We first sought to validate the functionality of the new allele. To this end, primary 214 cortical neurons of homozygous Fus^{exon15} mice were transduced with CRE using an adenoviral 215 vector (Ad-CRE). We observed Ad-CRE dose-dependent recombination of the Fus locus 216 (Figure S1B), as well as decreased immunoreactivity to NLS FUS antibody (Figure S1C). To 217 specifically mislocalize FUS in adult projection neurons, we crossed Fusexon15 mice with 218 transgenic mice expressing tamoxifen-inducible CRE specifically in excitatory projection 219 neurons (Thy1^{CRE-ERT2} mice (Young et al., 2008)). These mice also express YFP from the same 220 construct allowing the unambiguous identification of targeted cells (Young et al., 2008). Through two cross-breeding steps we generated Thy1^{CRE-ERT2}/ Fusexon15 mice, either 221 222 homozygous or heterozygous for Fusexon15. Control mice were littermate Fusexon15 homozygous 223 mice, devoid of Thy1^{CRE-ERT2} transgene. All mice underwent 5 days of Tamoxifen gavage at 6 224 weeks of age and molecular analyses were performed 10 weeks after the induction of 225 recombination (Figure 3A). Genotyping showed that a fraction of the Fus allele was efficiently 226 recombined (Figure S2A). This recombination led to increased total Fus mRNA (Figure S2B) 227 and mutant Fus mRNA as detected using RT-qPCR (Figure S2C). Moreover, 228 nuclear/cytoplasmic fractionation followed by western blotting showed decreased 229 immunoreactivity of FUS using an antibody targeting the C-terminal NLS, as well as increased 230 cytoplasmic levels of FUS using an antibody recognizing the N-terminal domain in cortical extracts of Thy1^{CRE-ERT2}/ Fus^{exon15} mice (Figure 3B-C). Moreover, we observed increased 231 232 cytoplasmic FUS staining when using an antibody targeting N-terminal FUS (Figure 3D) while 233 FUS NLS immunoreactivity disappeared in YFP-positive (hence recombined) cells in the

frontal cortex (**Figure S3A**, quantified in **Figure S3B**). Lastly, Thy1^{CRE-ERT2}/*Fusexon15* cortex showed hallmarks of FUS dysfunction as illustrated by an upregulation of *Taf15* (**Figure S4A**), as well as decreased inclusion of introns 6 and 7 of the *Fus* gene or of *Sfpq* intron 9 (**Figure S4B-D**), all of which are previously documented molecular alterations downstream of FUS mislocalization (Humphrey et al., 2020; Luisier et al., 2018; Sanjuan-Ruiz et al., 2021; Tyzack et al., 2019; Tyzack et al., 2021). As a whole, these results show that the recombination was efficient, and led to the mislocalization of FUS selectively in CPNs.

241

242 Having established an animal model with isolated FUS mislocalization in adult CPNs, we first 243 sought to determine whether this intervention recapitulated the gene expression fingerprint 244 observed in both patients and Fus^{ΔNLS/+} mice. We performed high-depth bulk RNA sequencing in the frontal cortex of Thy1^{CRE-ERT2}/ Fus^{exon15} mice and control mice 2.5 months after 245 246 recombination, which showed strong downregulation of the FUS regulon eigengenes (Figure 247 **3E**). Beyond the FUS regular eigengenes, we identified 1127 differentially expressed (DE) genes between Thy1^{CRE-ERT2}/ Fus^{exon15} mice and controls (FDR <0.05) (Figure S5A) that were 248 249 mostly related to neuronal projection and synapses (Figure S5B-C). Consistent with altered 250 synaptic and electrical activity, Thy1^{CRE-ERT2}/ Fus^{exon15} mice developed increased spike event 251 activity as recorded upon longitudinal electrocorticography at 12 and 20 weeks of age (i.e. 6 252 and 14 weeks after tamoxifen) (Figure 3F-G). We then counted NeuN-positive neurons 10 253 weeks after recombination in both frontal and motor cortex using semi-automated counting 254 procedures (Figure 3H) and observed a significant loss of neurons in both regions (Figure 3I-255 K). Thus, adult-onset mislocalization of FUS triggers molecular and electrical alterations, as 256 well as neuronal loss observed in ALS patients.

257

Adult-onset FUS mislocalization in cortical projection neurons phenocopies ALS-ci and ALS-bi

260 We did not observe weight loss or decreased motor performance in the inverted grid and grip tests conducted in Thy1^{CRE-ERT2}/ Fus^{exon15} mice (Figure S6A-D, Figure S7A). Consistent with 261 262 preserved motor function, lower motor neurons counts were unaltered despite efficient FUS 263 mislocalization in these cells (Figure S6E-G). As ALS is also associated with impaired 264 cognitive and behavioral function in ALS-ci and ALS-bi patients(Abrahams, 2023), we evaluated executive functions in Thy1^{CRE-ERT2}/ Fus^{exon15} mice (Figure 4A). We observed that 265 Thy1^{CRE-ERT2}/ Fus^{exon15} mice displayed a lower mean score and a higher number of untorn 266 267 cotton pieces when building their nests as compared to control mice (Figure 4B-C), suggesting 268 that the truncation of FUS in adult CPNs of mice leads to difficulties in planning, or planning 269 and executing the successive steps involved in nesting. To assess the general sociability and 270 interest in social novelty of Thy1^{CRE-ERT2}/ Fus^{exon15} mice, we then performed the three-chamber 271 test six weeks after induction of recombination. We first assessed the social preference of mice 272 by presenting them a cage containing a mouse and an empty cage, and by measuring the time 273 spent touching and sniffing them. We observed, as expected, that control mice spent 274 significantly more time with the mouse (Figure 4D, solid black line) than with the empty cage 275 during the first two trials (Figure 4D, dotted black line). This was also true for Thy1^{CRE-ERT2}/ 276 *Fus^{exon15}* mice but they showed significantly less interest that the control mice (**Figure 4D**, solid 277 versus dotted blue lines). We then assessed social memory of mice by presenting them a 278 known mouse (i.e. the one already met during the social preference phase of the test) and a 279 novel mouse. We observed that the contacting time of Thy1^{CRE-ERT2}/ Fusexon15 mice with the 280 novel mouse was significantly lower compared to that of control mice (p < 0.001). As a 281 consequence, the recognition index was significantly decreased (towards chance level) 282 compared to that of control mice (Figure 4E-F). These results were replicated in another paradigm, the resident intruder test (Figure 4G-H), thus highlighting impairments in social 283 functions, and in particular decreased social interest, in Thy1^{CRE-ERT2}/ Fusexon15 mice. 284 285 Contrastingly, adult neuronal FUS mislocalization was not sufficient to trigger general memory 286 defects as evidenced by an unaltered short-term or long-term object recognition (Figure 4I-J).

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Importantly, these mice did not suffer from generalized anxiety (Figure S7B-D) or lack of motivation (Figure S7E-G) that could explain sociability alteration. Thus, adult onset mislocalization of FUS in CPNs selectively impairs executive function, social interaction and social memory but preserves motor function or novel object recognition task. In all, adult onset mislocalization of FUS in CPNs provides a mouse phenocopy of ALS-ci/bi patients in the absence of motor symptoms.

293

294 FUS pathology and downregulation of the FUS regulon in patients with ALS-ci

295 Our results in mice provided a causal link between cytoplasmic FUS mislocalization and 296 cognitive and behavioral impairment. We then sought to determine whether this relation could 297 be observed in ALS-ci patients. To this aim, we selected 6 deeply clinically 298 phenotyped C9ORF72 cases with post-mortem tissue paired with regional cognitive scoring 299 performed for that functional domain. We selected BA39 as a language processing brain region 300 that had been assessed during life using the Edinburgh Cognitive ALS Screening (ECAS) tool. 301 Cases were stratified into ALS-ci (ECAS language domain score < or = 26) and ALS (ECAS 302 language domain score >26) based on published diagnostic cutoffs. Cases with ALS-ci 303 exhibited evidence of FUS pathology (cytoplasmic and nuclear pathology) (Figure 5A), which 304 was less frequently encountered in ALS cases that were cognitively intact (Figure 5B-C). 305 Indeed, FUS pathology, guantified using digital burden scoring (Rifai et al., 2022) correlated 306 with ECAS score in this region scale (Figure S8) demonstrating that the burden of FUS 307 pathology, measured in a non-biased way, correlates with cognitive function in these cases. 308 To provide orthogonal evidence of altered FUS function in ALSci, we re-analyzed our dataset 309 of snRNAseg in ALS and ALS-ci patients in frontal regions BA44 and BA46 (Petrescu et al., 310 2025) and merged this dataset with previously published BA4 and BA9 regions involved in 311 motor control (Pineda et al., 2024). We identified 287,275 excitatory neurons and, among those 312 1,547 L5-ET neurons, that expressed typical L5-ET expression markers such as ADRA1A, 313 POU3F1, VAT1L and SULF2 (Figure 5D-E). Merging the two datasets revealed two L5-ET 314 subtypes, with their own expression markers (Figure 5E) and different distributions across 315 cortical regions studied (Figure 5F). Importantly, we observed a diminished proportion of L5-316 ET neurons, but not L5-IT neurons, in ALS, and even more in ALSci patient (Figure 5G-H) in 317 these datasets, further confirming the selective involvement of this neuronal population in ALS 318 and ALSci. Importantly, expression of the FUS regulon was significantly downregulated in L5-319 ET and L5-IT neurons of ALSci patients as compared to controls (Figure 5I). ALS patients 320 showed an intermediate situation with decreased expression of the FUS regulon only in L5-IT 321 neurons (Figure 5I). This relationship between cognitive impairment and FUS regulon 322 expression in L5-ET neurons was also observed at the individual patient level (Figure 5J) and 323 there was a positive correlation between FUS regulon expression in L5-ET neurons and total 324 ECAS scores of studied patients (Figure 5K). Strikingly, this relationship was mostly observed 325 in BA46, involved in executive function, as compared to BA44 (Figure 5L). Last, we sought to 326 determine whether cognitive function and FUS dysregulation could be related to an 327 accumulated genetic burden of dementia. To answer this question, we processed whole 328 genome-sequencing of patients with ALS and ALSci (Petrescu et al., 2025), and filtered out 329 gene variants involved in dementia to compute a genetic burden that could be correlated with 330 FUS regulon expression and cognitive function (Figure 5M). Indeed, a high genetic burden 331 (>2 missense variants) was associated with decreased ECAS score (Figure 5N) and, at the 332 individual patient level, ALSci patients showing a higher genetic burden (Figure 5J). 333 Accumulation of deleterious missense variants led to decreased cognitive performance in 334 executive, language or memory subscores (Figure 50). Consistently, expression of the FUS 335 regulon was negatively correlated to genetic burden of dementia (Figure 5P). In all, our results 336 suggest that ALSci develops in ALS patients with increased genetic burden of dementia, 337 leading to cytoplasmic FUS mislocalisation and decreased expression of FUS downstream 338 target genes in L5-ET vulnerable neurons.

340 The FUS regulon is enriched in ALS genetic risk and allows for prioritizing novel ALS-

341 ci/bi genes

342 Our previous results provided indirect evidence that FUS and its regulated genes might lie in 343 the same genetic pathway than other dementia related genes. Interestingly, the heritability of 344 ALS is enriched in FUS binding sites (Megat et al., 2023). We thus hypothesized that the FUS 345 regulon could be enriched in ALS-risk genes, and we applied stratified linkage disequilibrium 346 (Bulik-Sullivan et al., 2015) (LD) score regression (S-LDSC) to the most recent ALS genome-347 wide association study (GWAS)(van Rheenen et al., 2021) (Figure 6A). We compared ALS 348 heritability estimates in FUS regulon gene to a randomly sampled gene set over 10 iterations 349 and used ALS GWAS data as a positive control. As shown in Figure 6B, FUS regulon genes 350 are enriched in ALS heritability (E=87.7 fold, *Bonferroni p < 0.05). As expected, we observed 351 a strong enrichment of the ALS GWAS (E=387.3 fold, *Bonferroni p < 0.05) but no enrichment 352 in the randomly sampled gene set (Bonferroni p > 0.05). These results suggest that the FUS 353 regulon is highly enriched in ALS heritability and might contain new potential ALS genes. Then, 354 we sought to refine our analysis through the comparison of the FUS regulon with genes known 355 to cause ALS, ALS-FTD or pure FTD. When overlapping genes in the FUS regulon with a 356 curated list of ALS genes, we observed a significant enrichment of genes involved in ALS-357 FTD, including (FUS, KIF5A, C9ORF72, ERBB4, HTT or GBA) (Fisher's exact test; p=2.2.10⁻ 358 ⁰⁶) (Figure 6C). 359

360 Having shown that FUS regulon expression is altered in ALS-ci and is enriched in ALS-FTD 361 risk genes we sought to test whether the FUS regulon could help us prioritizing new genetic 362 risk factors associated with either ALS-ci or ALS-bi. To do so, we analyzed whole genome 363 sequences (WGS) from 546 ALS patients of the Answer ALS cohort who have been evaluated 364 for cognitive and behavioral impairment through questionnaire screening according to ALS 365 cognitive Behavioral Screen (ALS-CBS) scale (Figure 6D) (Baxi et al., 2022).WGS SNPs were 366 filtered to map FUS regulon genes resulting in a final set of 131,202 SNPs falling onto at least

367 one gene of the FUS regulon. Interestingly, we observed that rs11991627 located in the 368 FBXO16 gene is significantly associated with the risk of ALS-bi (Logistic regression: OR = 3.22369 (1.94-4.23) p=5.44.10⁻⁰⁷) while it does not associate with ALS-ci (Logistic regression: OR = 370 1.30 (0.16-2.45) p=0.098) (Figure 6E-H). Conversely, we observed a suggestive association 371 of rs12324967 in the WWOX gene, previously associated with cognitive impairment in 372 Parkinson's disease (Liu et al., 2021), with ALS-ci (Logistic regression: OR = 0.28 (0.03-1.43) 373 p=5.08.10⁻⁰⁵) (Figure 6E-H). The rs11991627 allele in FBXO16 shows an additive effect on 374 behavioral score (One-way ANOVA: *** p=1.31.10⁻⁰⁶), suggesting that FBXO16 rs11991627 375 carriers have increased risk of behavioral impairments associated with diagnosed ALS (Figure 376 61). These results show that the FUS regulon includes novel genes associated to cognitive 377 and/or behavioral impairment in ALS, including FBXO16 or WWOX.

378

379 FBX016 PTV carriers show behavioral abnormalities, fronto-temporal atrophy and 380 increase expression of fluid biomarkers associated with dementia.

381 We then sought to independently validate whether variants in FBXO16 could represent risk 382 factors for ALS-FTD related cognitive impairment. To this end, we leveraged large-scale UK 383 Biobank data (Sudlow et al., 2015). In UK Biobank, we identified carriers of FBXO16 protein-384 truncating variants (PTV) and tested whether these individuals displayed behavioral, imaging 385 or protein biomarker changes associated with ALS and/or FTD (Figure 7A). We identified 231 386 FBXO16 PTV carriers (n=231), and observed increased risk associated with behavioral and 387 emotional states in these individuals (R45 category: *Bonferroni corrected-p < 0.05) (Figure 388 **7B**). The R45 subcategory of symptoms reported in the UK-Biobank dataset includes apathy, 389 social isolation and irritability, and we observed that FBXO16 PTV carriers showed increased 390 risk of hostility behaviors (logistic regression: *Bonferroni corrected-p < 0.05), irritability 391 (logistic regression: *Bonferroni corrected-p < 0.05) and nervousness (logistic regression: 392 *Bonferroni corrected-p < 0.05). Moreover, we also observed a suggestive association with

393 apathic behavior (logistic regression: p=0.018) (Figure 7B). These results suggest that 394 carrying a FBXO16 PTV variant leads to behavioral abnormalities generally associated with 395 ALS-bi.

396 Next, we sought to test whether FBXO16 PTV carriers could show altered brain connectivity 397 and structure, and used the diffusion MRI and T1 structural MRI datasets (Littlejohns et al., 398 2020; Miller et al., 2016). Using image-derived phenotypes (IDPs) from diffusion MRI, we 399 performed an unbiased association analysis to test whether FBXO16 PTV carriers show 400 altered white matter structure evidenced by a decrease in fractional anisotropy (FA) or axial 401 diffusivity. Indeed, FBXO16 PTV carriers (n=13) showed a large decrease in FA in the genu of 402 corpus callosum (GLM regression: FDR<0.05) and decreased axial diffusivity in the left 403 uncinate fasciculus (GLM regression: FDR<0.05) when compared to non-carriers individuals 404 (n=37,817) (Figure 7C). Interestingly, previous studies showed a loss of white matter in the 405 genu of the corpus callosum in patients diagnosed with behavioral variant FTD(Elahi et al., 406 2017; Mahonev et al., 2015) and decreased FA in the left uncinate fasciculus in patient 407 diagnosed with behavioral variant FTD (Mahoney et al., 2015) that correlate with symptoms 408 severity (D'Anna et al., 2016). Using a whole-brain connectomics analysis and focusing on the 409 left uncinate fasciculus, we observed that FBXO16 PTV carriers display a lower number of 410 white matter tracts (unpaired t-test;*p<0.05) connected to distinct frontal region such as the 411 pars orbitalis (BA47), the pars triangularis (BA45) and the rostral medial frontal cortex (BA46) 412 (*Fisher's exact test;*p<0.05) (Figure 7D-F), that are all parts of the inferior frontal gyrus 413 (Broca's area) with crucial role in semantic tasks and working memory (Munoz-Neira et al., 414 2019). As FBXO16 PTV carriers showed strong alteration in white matter integrity in a specific 415 region of the left frontal cortex, we studied possible grey matter changes and analyzed T1-MRI 416 scans from FBXO16 PTV carriers and non-carriers. We observed that FBXO16 PTV carriers 417 showed a strong decrease in area and volume of the left frontal regions that correspond to the 418 pars triangularis (BA45) (Cluster-correlation; FDR<0.05) (Figure 7D-F). Region-specific ROI 419 analysis indicated a significant decrease of the area (unpaired-t-test; **p<0.01) and volume 420 (unpaired-t-test; *p<0.05) in the left pars triangularis (BA45) region in FBXO16 PTV carriers 421 while no differences were observed in the right hemisphere (Figure 7G). Finally, we studied 422 whether FBXO16 PTV carriers show altered plasma protein biomarkers associated with 423 neurodegenerative diseases. Using the prospective UK-Biobank Olink-based proteomic cohort 424 (Sun et al., 2023), we selected individuals with incident neurodegenerative disorders including 425 ALS and dementia. After guality control and inclusion of age and sex-matched individuals 426 across diseases, we included 24,557 adults without ALS or dementia in the UK Biobank, along 427 with 1,073 incident cases and a follow-up time of 8.6 years. During this follow-up, 884 (3.7%) 428 incident dementia cases were identified, of which 118 occurred within 5 years, 350 within 429 10 years and 415 beyond 10 years. In this population, we observed increased plasma 430 neurofilament light chain (NEFL) (*GLM p* = $1.96.10^{-06}$) and glial fibrillary acidic protein (GFAP) 431 proteins (GLM $p = 1.96.10^{-06}$) in FTD (Figure 7H). These two proteins were also altered in 432 different dementia subtypes, including Alzheimer's disease (Bonferroni corrected p <0.05) and 433 vascular dementia (Bonferroni corrected p <0.05) (Figure 7H). In this population, there were 434 also 223 patients diagnosed with ALS, of which 108 occurred within 5 years, 93 had incidents 435 within 10 years and 22 had incidents over 10 years. Interestingly, plasma GFAP expression 436 was unchanged in pure ALS (GLM p > 0.05) while NEFL was significantly increased 437 (Bonferroni corrected p < 0.05) in incident dementia, in line with previous studies (Guo et al., 438 2024; Katisko et al., 2021). Interestingly, FBXO16 PTV carriers showed significantly elevated 439 levels of GFAP protein (permuted-p<0.05) as well as NEFL (permuted-p<0.01) (Figure 7H). 440 Altogether, our results show that loss of FBXO16 is associated with behavioral, neuroimaging 441 and plasma biomarker evidence of altered fronto-temporal network, consistent with prodromal 442 ALS/FTD.

444 Discussion

445

446 Neurodegenerative diseases are defined by three major characteristics: a core set of 447 symptoms (progressive paralysis for ALS), loss of specific neuronal populations and a typical proteinopathy (TDP-43 for ALS). However, the clinical picture associated with a specific 448 449 neurodegenerative disease can include additional symptoms in some patients. In ALS, for 450 instance, a substantial fraction of patients develops cognitive impairments. In these ALS-ci 451 patients, the relation between cognitive impairment and TDP-43 pathology is unclear (Bampton 452 et al., 2024; Rifai et al., 2024; Suzuki et al., 2024). In most neurodegenerative diseases, 453 proteinopathies are frequently mixed, and the occurrence of multiple pathologies is generally 454 related to more severe cognitive impairment. However, the contribution of individual 455 pathologies to the heterogeneity of symptoms is unclear (Forrest and Kovacs, 2024; 456 Maldonado-Diaz et al., 2024). Furthermore, in ALS and FTD, FUS proteinopathy is generally 457 overlooked as it may involve cytoplasmic mislocalization rather than aggregation (Rifai et al., 458 2022; Tyzack et al., 2019).

459 A first important result of this study is that FUS mislocalization in CPNs drives ALS-ci/bi-like 460 impairments in ALS. This result is substantiated by correlative evidence in patients as FUS 461 mislocalization in CPNs is observed in ALS-ci patients, but not in those without cognitive 462 impairments. Consistently, the typical signature of FUS-related dysfunction was observed in 463 L5-ET neurons of ALS-ci patients and related to cognitive impairment at the individual patient 464 level. Whilst the absence or presence of TDP-43 pathology is associated with the absence or 465 presence of cognitive dysfunction (Gregory et al., 2020), no protein misfolding pathology has 466 previously been shown to correlate with the burden of symptoms, highlighting the importance 467 of this finding with respect to FUS. Beyond correlative evidence, we provide functional, in vivo, 468 evidence that mislocalization of FUS in adult CPNs is sufficient to drive cognitive and 469 behavioral impairment in a novel mouse model. These behavioral abnormalities were observed 470 a few weeks after the induction of FUS mislocalization and phenocopied cognitive and 471 behavioral impairments in ALS-ci/bi patients. Contrastingly, these mice were spared of motor 472 defects even after more than one year of follow up. This finding indicates that the occurrence 473 of FUS mislocalization in CPNs might drive cognitive impairment in ALS patients already 474 presenting the motor symptoms. Our current results suggest that FUS mislocalization should 475 be systematically included in the pathological characterization of ALS-ci/bi patients, and, 476 beyond in neurodegenerative diseases with cognitive and behavioral impairments.

477 How could FUS mislocalization be triggered in CPNs of ALS-ci/bi patients? In rare cases, ALS 478 patients carry germline mutations of FUS that increase FUS mislocalization(Kwiatkowski et al., 479 2009; Vance et al., 2009). These mutations generally lead to severe motor phenotypes and 480 there are few studies characterizing possible cognitive impairments in these FUS-ALS 481 patients. However, learning disabilities and mental retardation have been observed in FUS-482 ALS patients especially in severely affected patients (Goldstein et al., 2022; Grassano et al., 483 2022; Hirayanagi et al., 2016; Lanteri et al., 2021). There are also reports of patients with FUS 484 variants showing fronto-temporal dementia phenotype either isolated or with an initial 485 presentation of ALS-FTD(Aguzzoli et al., 2022; Broustal et al., 2010; Van Langenhove et al., 486 2010). However, most ALS-ci patients do not present a germline FUS mutation, and FUS 487 mislocalization is likely, in these cases, secondary to other pathogenic events. In cell models, 488 FUS mislocalization can be elicited by various stresses including arsenite (Bosco et al., 2010; 489 Dormann et al., 2010; Szewczyk et al., 2023), osmotic stress (Gao et al., 2022; Hock et al., 490 2018), antiviral response (Bellmann et al., 2019; Shelkovnikova et al., 2019) or nuclear pore 491 defects (Lin et al., 2021), suggesting the contribution of environmental insults to FUS 492 mislocalization. In addition, pathological mislocalization of FUS could also result from 493 aggregation of other RNA-binding proteins, such as TAF-15 (Tetter et al., 2024) in FTLD-FET,

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

494 or from pathological spreading of FUS from neighboring cells (Vazquez-Sanchez et al., 2024). 495 Last, FUS mislocalisation could also result from increased genetic burden that ultimately drives 496 this pathological hallmark in vulnerable neurons. The latter mechanism is supported by our 497 observation of increased dementia-related genetic burden in ALSci patients that correlates 498 with the extent of FUS regulon downregulation. It is however very likely that a conjunction of 499 these different mechanisms leads to FUS mislocalisation and downregulation of the FUS 500 regulon in vulnerable L5-ET neurons. Whatever the underlying cause of FUS mislocalization, 501 our study demonstrates that its induction in adult CPNs is on its own sufficient to lead to ALS-502 ci relevant cognitive symptoms.

503 A second major result of our study is that FUS mislocalization drives genetic risk of cognitive 504 and behavioral impairment in ALS. A previous survey of relationships between RBPs binding 505 targets and ALS heritability showed that target binding sites of 6 RBPs, including TDP-43 and 506 FUS, were associated with ALS risk(Megat et al., 2023). This finding is consistent with the 507 major GWAS hit UNC13A being a TDP-43 target(Brown et al., 2022; Ma et al., 2022). However, gene targets of TDP-43 or FUS are cell-type dependent(Jeong et al., 2017), and it was critical 508 509 to identify those in CPNs. Here we identify a set of genes regulated by FUS mislocalization in 510 CPNs through a cross-species approach. This cross-species approach increases the 511 robustness of target identification by conserving them across species and cell types, but is 512 conservative. We cannot exclude that additional, human-specific FUS-regulated genes could 513 be missing from the current FUS-regulated gene list. It is unlikely that all these FUS-regulated 514 genes share a unique FUS-dependent regulatory mechanism as FUS is a multi-functional 515 RNA-binding protein, involved at all steps of gene expression, from transcription to splicing, 516 local translation or microRNA-mediated regulation (Lagier-Tourenne et al., 2010; Picchiarelli 517 et al., 2019; Piol et al., 2023). It is also possible that some of these FUS regulon genes are 518 indirect FUS targets and the precise mechanisms linking these genes to FUS will have to be 519 determined on a gene-by-gene basis in further studies. Importantly, TDP-43 also regulates 520 RNA levels of FUS-regulon genes suggesting that convergent loss of function of FUS and 521 TDP-43 could synergize in leading to ALS neurotoxicity (Lagier-Tourenne et al., 2012).

522 ALS-linked genes were significantly enriched in the FUS regulon, and a substantial number of 523 ALS genes were present in this regulon, including familial genes (C9ORF72, KIF5A, ERBB4, 524 FUS itself), but also genes with common ALS-associated variants such as NEK1, SCFD1 or 525 SARM1. Interestingly, genes of the FUS regulon are associated with ALS with 526 cognitive/behavioral impairment including C9ORF72 (Diekstra et al., 2014), KIF5A (Dulski et 527 al., 2023; Saez-Atienzar et al., 2020), FUS (Aguzzoli et al., 2022; Broustal et al., 2010; Van 528 Langenhove et al., 2010), ERBB4(Sun et al., 2020), or SCFD1(Chen et al., 2024). This finding 529 suggests that the genes of the FUS regulon could be enriched in genes relevant for ALS-ci 530 and ALS-bi rather than pure ALS. Consistently, we were able to uncover robust genetic 531 associations between common variants in FBXO16 and WWOX with ALS-bi and ALS-ci 532 respectively. WWOX has been genetically associated with Alzheimer's disease (Kunkle et al., 533 2019) and to risk of cognitive progression in Parkinson's disease (Liu et al., 2021), and dementia in limbic-predominant age-related TDP-43 encephalopathy neuropathological 534 535 change (LATE-NC), hippocampal sclerosis, and brain arteriolosclerosis (Dugan et al., 2022) 536 indicating that this gene is broadly associated to cognitive deficits in multiple 537 neurodegenerative diseases. WWOX encodes for a protein of poorly characterized function 538 that has been suggested to indirectly modulate transcriptional activity and cell proliferation 539 (Kosla et al., 2019). Its function in neurons is poorly documented, but it is worth noting that 540 loss-of-function mutations are also associated with WWOX-related epileptic encephalopathy 541 (WOREE) syndrome characterized by intractable epilepsy, severe developmental delay, motor 542 deficits and premature death at the age of 2-4 years (Mallaret et al., 2014). Consistently, 543 ubiquitous or neuronal deletion of Wwox in mice leads to a complex neurodevelopmental and

- 544 neurodegenerative phenotype (Cheng et al., 2020; Repudi et al., 2021). Our results suggest
- 545 that mild loss of WWOX could sensitize to cognitive impairment during ALS, thereby favoring
 - 546 an ALS-ci clinical picture.

547 We also show a genetic association between FBXO16 and ALS-bi, and loss of FBXO16 in 548 PTV carriers is sufficient to lead to multiple abnormalities in behavior, neuroanatomy and 549 circulating biomarkers all consistent with fronto-temporal damage. FBXO16 encodes for a 550 largely uncharacterized F-box containing protein, F-box containing proteins are well known for 551 their E3 ubiquitination ligase function in the SCF complex (SKP1-CULLIN1-F-box protein) and 552 it is thus likely that FBXO16 is important in the ubiquitination and possibly degradation of 553 specific, currently unknown, substrates(Wang et al., 2014). In cancer cells, FBXO16 has been 554 shown to inhibit the beta-catenin pathway through proteosomal targeting of nuclear beta-555 catenin (Khan et al., 2019; Paul et al., 2019). Whether this function is related to behavioral 556 impairment in FBOX16 PTV carriers or in ALS-bi patients carrying FBXO16 common variant 557 remains to be determined. Nonetheless, our newly defined association between FBXO16 and 558 ALS-bi, indicates that perturbations in proteostasis likely contribute to disease pathogenesis.

559 In totality, our study demonstrates that additional FUS pathology is a contributor to cognitive 560 impairment occurring in ALS patients and is related to the genetic risk of ALS-related cognitive 561 and behavioral impairments. We further identify and replicate FBXO16 as a novel gene 562 contributing to behavioral impairments in ALS.

563

Methods 565

566

567 Patients tissue staining

568 Ethics:

569 All clinical data including the ECAS were collected as part of Scottish Motor Neuron Disease 570 Register (SMNDR) and Care Audit Research and Evaluation for Motor Neuron Disease 571 (CARE-MND) platform (ethics approval from Scotland A Research Ethics Committee 572 10/MRE00/78 and 15/SS/0216) and all patients consented to the use of their data during life. 573 All post-mortem tissues were collected via the Edinburgh Brain Bank (ethics approval from 574 East of Scotland Research Ethics Service, 16/ES/0084) in line with the Human Tissue 575 (Scotland) Act. Use of human tissue for post-mortem studies has been reviewed and approved 576 by the Edinburgh Brain Bank ethics committee and the Academic and Clinical Central Office 577 for Research and Development (ACCORD) medical research ethics committee (AMREC). 578 BA39 was selected as a brain region that assesses language function and had been evaluated 579 in at least 6 C9ORF72 patients with 3 demonstrating impairment (as measured by clinically 580 approved cut-offs measured by the Edinburgh Cognitive ALS Screening tool (Gregory et al.,

- 581 2020). BA4 was used as a representative region of the motor cortex.
- 582

583 Immunohistochemical staining:

584 Immunohistochemistry was performed on 4 μ m-thick sections on superfrost charged slides. 585 Sections were deparaffinized, followed by antigen retrieval using citric acid pH6. Sections were 586 then stained using the Novolink Polymer detection system (DAB chromogenic staining) using

587 FUS primary antibody (BioTechne NB100-595) at 1 in 500 dilution. Counterstaining was 588 performed using lithium carbonate and haematoxylin. Slides were imaged using an EVOS

- 589 M5000 microscope using brightfield settings at 10x and 40x magnification.
- 590

591 Mouse breeding and genotyping

592 Mice were housed in our animal facility (Strasbourg), with a regular 12h light and dark cycle 593 under constant conditions (21 ± 1°C, 60% humidity) and unrestricted access to food and water. 594 Double transgenic mice were generated by crossing Thy1.2 CreERT2 mice (The Jackson 595 Laboratory, JAX stock #012708 STOCK Tg(Thy1-cre/ERT2,-EYFP)HGfng/PyngJ) (Caroni, 596 1997; Feil et al., 1997; Young et al., 2008) with mice carrying the nuclear localization signal 597 (NLS) of Fus flanked by two LoxP sequences (Mouse Clinical Institute of Strasbourg, 598 Phenomin-ICS). We obtained offspring in which a tamoxifen-inducible Cre-mediated 599 recombination aimed at deleting the NLS of FUS specifically in long projection neurons. We 600 used mice containing two alleles with a LoxP-flanked Fus NLS sequence (FusLoxP/LoxP. 601 referred to as "Fusexon15") and homozygous double mutant mice (Thy1.2 CreERT2 FusLoxP/LoxP, referred to as "Thy1-Fusexon15 mice"). Mice were carefully handled to reduce 602 603 their stress and anxiety. Experimental protocols and animal care complied with the institutional 604 guidelines (council directive 87/848, 19 October 1987, Ministry of Agriculture and Forestry, 605 Veterinary Department of Health and Animal Protection) and international laws (directive 606 2010/63/UE609, 13 February 2013, European Community) and policies (personal 607 authorization #I-67UnivLouis Pasteur-F1-04 for R.C.). The project has been approved by the 608 ethics committee of Strasbourg (CREMEAS, reference number: FUS NLS inductible_#12173-609 2018062510569395).

610

611 **Primary neuronal cultures**

612 Primary cortical cells were taken from homozygous Fusexon15 E145 mouse embryos and 613 cultured in complete neurobasal medium, i.e. Neurobasal medium (Thermofisher) 614 supplemented with 1% Penicillin/Streptomycin (Sigma), 1%GlutaMAX (ThermoFisher) and 2% 615 B27 (ThermoFisher). Dissected cortices were incubated with trypsin/EDTA (Sigma) and 616 DNAse (50U/ml final_Sigma), washed, and triturated to give a single cell suspension. Cells

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

617 were cultured for 3-4 h in complex neurobasal medium complemented with 10% FBS 618 (Thermofisher). From day 1 to day 14, we used complete neurobasal medium and changed 619 the medium every 2-3 days. Cultured neurons were then exposed to an adenoviral vector (Ad-620 CRE-GFP, Vector biolab, #1700 and ad-CMV-GFP, Vector biolab, #1060 as control) at MOI 1,

- 621 10, and 100 either 5 or 14 days after plating.
- 622

623 Induction of recombination in adult mice

624 The recombination was induced at 1.5-months of age by forced-feeding mice of both 625 genotypes (*Fus*^{exon15} and Thy1-*Fus*^{exon15} mice) with 100 μ L of tamoxifen at 20 mg/mL (Sigma) 626 diluted in Corn oil (Sigma) for 5 consecutive days. We waited another month and a half before 627 doing the different procedures (i.e. behavioral studies or dissection for biochemical analyses).

628

629 Behavioral studies in mice

630 All behavioral studies were made in the morning during the light phase and the experimental 631 procedure started after a 30-minute period of habituation to the experimental room. Mice were 632 handled for at least five days to reduce stress and anxiety due to manipulation.

- 633
- 634 Motor test
- 635 Mice were subjected to the inverted grid test to noninvasively assess the ability of mice to use
- 636 sustained limb tension to oppose their gravitational force(Carlson et al., 2010). Each mouse
- 637 was placed on a grid and was allowed to adapt to this environment for 15-20 s. The grid was
- 638 then inverted and held approximately 35 cm over a cage containing 5 cm of wood chips. We
- 639 assessed the hanging time, i.e. the time the mice hold before falling, for three trials with 5-
- 640 minute breaks between each and a cut-off time of 5 min. The mouse body mass was measured
- 641 shortly before the test to compute the minimal total sustained force that was exerted to oppose
- 642 the gravitational force: holding impulse (N.s) = averaged hanging time (s) \times body mass (g) \times 0.00980665 (N.g⁻¹).
- 643 644
- 645 Nest building test
- 646 Nesting abilities were measured based on a previously described protocol(Deacon, 2006). One 647 hour before the dark phase, enrichment items were removed from individual home cages and
- 648 3 g of pressed cotton pieces (i.e. approximately 6 pieces) were given to each mouse. After 24h
- 649 nests were assessed with the five-point scale used by Deacon(Deacon, 2006). Untorn cotton 650 pieces were counted and weighed.
- 651

652 Three-chamber social task

653 The experimental procedure was adapted from Gascon E et al (Gascon et al., 2014). The three-654 chamber box (59 × 39.5 × 21.5 cm) is made of transparent Plexiglas (Noldus Information 655 Technology, Wageningen, The Netherlands) and is divided into three chambers (one middle 656 and two side chambers) of equal size $(18.5 \times 39.5 \text{ cm})$ by the walls with a square opening (7 657 × 7 cm) that could be closed by a slide door. Each tested mouse was placed in the middle of 658 the central compartment that was kept empty while the two others compartments contained an 659 openwork cylindrical cage (20 × 10 cm diameter made of transparent Plexiglas bars). After the 660 habituation session (one trial with free access of the arena containing two empty cages), mice 661 were placed three times (15-minute inter-trial interval) in the arena containing a cage with a 662 mouse (referred to as "mouse"") and an empty cage. Mice were placed one last time in the 663 arena containing a cage with the known mouse (i.e. the mouse already meet tree times during 664 the previous phase) and a cage with a novel mouse (referred to as ""Novel mouse"). For all 665 sessions, mice were free to explore the arena for 5 min while being recorded. For all sessions, 666 mice were free to explore the arena for 5 min while being recorded. Two parameters were 667 measured using the EthoVision XT software (Noldus Information Technology) : total distance 668 travelled and velocity. The time spent contacting the empty cage and the strangers was

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

669 measured by hand. The recognition index (RI) was calculated according to this formula: RI = 670 contact time with stranger 2 / total contact time × 100.

671

672 Resident-intruder social task (social interaction in home cage)

Briefly, after 30 minutes of habituation to the test room resident mouse was allowed to freely roam in its home cage without the cage top for 1 min. A novel male intruder mouse (nonlittermate of the same background, same age, and similar weight) was introduced in the opposite corner as the resident. We recorded the interaction for 5 min to assess social activities: total physical interaction (active exploration of the intruder) comprising investigating, grooming, following and sniffing(Scekic-Zahirovic et al., 2021).

679 680 <u>Dark/light box test:</u>

681 The apparatus consisted of a polypropylene cage $(44 \times 21 \times 21 \text{ cm})$ separated into two 682 compartments with a small opening (12 x 5 cm) at floor level. The first compartment (28 cm 683 long) was open-topped, transparent, and brightly illuminated by white light from a 40-watt desk 684 lamp positioned above the lit chamber (140 lux). The second compartment is smaller (14 cm 685 long) and covered at the top with black Plexiglas and painted black on all sides. Mice were 686 individually placed in the center of the dark compartment and allowed to freely explore the 687 apparatus for 5 min. The apparatus was cleaned with a 30% ethanol solution between 688 subjects. We assessed the number of light/dark transitions between the two compartments, 689 the latency to first get out of the dark box, and the total time spent in the light compartment.

- 690
- 691 Object recognition test:

692 The novel object recognition test was performed to investigate learning and memory in 693 mice(Lueptow, 2017). Each mouse was placed in the middle of an open and squared arena 694 containing two objects. The position of these objects was the same for all sessions and the 695 objects and arena were cleaned with 70% (v/v) ethanol. For the habituation (day 1), mice were 696 placed two times, with a 10-minute break in between, in the arena containing two identical 697 objects (empty tips boxes). Object recognition was tested after a short retention time (10 min) 698 to evaluate short-term memory (day 2) and after a longer one (24h) to look at long-term 699 memory (days 3 and 4). Mice were first placed in the arena with two identical objects (either 700 two water glasses for short term memory or two glass bottles for long-term memory). Then, for memory assessment, one of the previous objects was replaced by a novel one (a 15-cm high 701 702 vial for short-term memory and stemmed glass for long term memory). For all sessions mice 703 were free to explore the arena during 10 min while being recorded. Two parameters were 704 measured using the EthoVision XT software (Noldus Information Technology): total distance 705 travelled and velocity. The times spent exploring the identical objects, the known object (Tk) 706 or the novel one (Tn) were manually determined. The recognition index (RI) was calculated 707 according to this formula: RI = exploration time of the novel object (Tn) / total exploration time 708 $(Tk + Tn) \times 100.$

709

710 <u>Sucrose splash test:</u>

The protocol, adapted from Isingrini et al. (2010),(Isingrini et al., 2010) consists of spraying a 10% sucrose solution on the dorsal coat of a mouse in its home cage. Due to sucrose's viscosity, the sucrose solution dirties the mouse fur and animals initiate grooming behaviors. Once the sucrose solution was applied, latency (time between spray and initiation of grooming) and duration of grooming were recorded for 5 minutes.

- 716
- 717 <u>Sucrose preference test:</u>

The Sucrose Preference Test (SPT) is a reward-based test used as an indicator of anhedonia. We used a protocol adapted from Serchov et al. (Serchov et al., 2016). Briefly, mice were presented for three days in their home cage with two identical-looking bottles, but one contains water while the other contains a sucrose solution (1%, EMD Millipore, catalog number:

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

573113). Consumption of water and sucrose solution was measured daily, and the positions of the two bottles were interchanged each day to reduce any risk of lateral bias. Sucrose preference (SP) was calculated as a percentage of the volume of sucrose intake over the total volume of fluid intake and averaged over the three days of testing according to this formula: SP = V(sucrose solution)/[V(sucrose solution)+V(water)] x 100%.

728 Electrocorticography in mice

729 Surgery:

727

730 Surgery procedures were similar to previous studies(Guillot et al., 2025; Scekic-Zahirovic et 731 al., 2024). Briefly, mice were deeply anaesthesized using 4% isoflurane (Baxter). Prior to the 732 procedure, injectable meloxicam (Metacam, 10mg/mL, Boehringer Ingelheim) was provided 733 subcutaneously to the animals. After local subcutaneous injection of lidocaine (Lurocaine, 734 2mg/kg, Vetoquinol), animals were stereotaxically implanted with electrodes at the following 735 coordinates: Reference electrode: Bregma +0.50mm, midline +0.00mm; Ground electrode: 736 Bregma -3.00mm, midline -3.00mm; Recording electrode 1: Bregma +2.50mm, midline 737 +2.00mm; Recording electrode 2: Bregma -2.50mm, midline -2.00mm. The incision was closed 738 using dental cement (Super-Bond C&B). The animals were returned to their home cage and 739 given meloxicam (Metacam, 5mg/mL, Boehringer Ingelheim) ad libitum in their drinking water 740 for five days after the procedure.

741

742 Analysis:

743 Electrocorticography (ECoG) recordings were conducted on Thy1^{CRE-ERT2}/Fus^{exon15} mice and 744 their respective control littermates at 3 and 5 months of age, over a 24-hour period. ECoG was 745 recorded using LabChart (LabChart version 5, ADInstruments, USA). ECoG signals were 746 collected with a 2,000Hz sampling rate. The Python package EEVop(Guillot, 2023) was used 747 to analyze the ECoG traces. To remove the powerline (50Hz) and its harmonics up to 200Hz, 748 ECoGs were notch-filtered. A Z-score was used to normalize each ECoG recording. The Z-749 score of each recording was compared with the mean Z-score of the control animals. Only 750 events that exceeded the baseline Z-score were counted. To ensure proper removal of background noise, a window discriminator of four times the baseline standard deviation was 751 752 used for event detection.

753

754 Immunostaining in mice and imaging

755 Immunolabelling experiments were performed 1.5 months after tamoxifen administration. The 756 mice were deeply anaesthetized using an intraperitoneal injection of pentobarbital (60 mg/kg) 757 and then transcardially perfused with cold 4% PFA in 0.01 M phosphate-buffered saline (PBS). 758 After dissection (brain and spinal were splitted), brains were post-fixed for 24 hours and then 759 included in agar 4% and serial cuts of 40 μ m thick were made using vibratome (Leica 760 Biosystems, S2000). After three washes (0.1M PBS), tissues were incubated for a 30 min 761 period in citrate sodium buffer (pH 6, 10 mM) at 85°C and then left for 90 min in PBS with 0,5% 762 Triton X-100 and 5% donkey serum under slow agitation. The primary antibodies were 763 incubated in 0.1% Triton X-100 and 1% donkey serum in PBS for 24h at 4°C: rabbit@FUS N-764 ter (Protein Tech, #11570-1-P, 1/250), rabbit@FUS C-ter (Bethyl, #A300-294, 1/500), 765 chicken@GFP (Abcam, #a13970, 1/1000), goat@ChAT (Millipore, #AB114P, 1/1000), 766 mouse@NeuN (Millipore, #MAB377; 1/250), goat@lba1 (abcam, #ab5076, 1/250), 767 rabbit@GFAP (Dakocytomation, 1/250). After three washes, the secondary antibodies were 768 incubated in 0.1% Triton X-100 in PBS overnight at 4°C: Alexa Fluor 488 donkey anti-chicken 769 IgG H&L (JacksonLab, #703-545-155 5, 1/500); Alexa Fluor 647 donkey anti-rabbit IgG H&L 770 (JacksonLab, #711-605-152, 1/500); Alexa Fluor 555 donkey anti-mouse IgG H&L (Molecular 771 Probe, #A21203, 1/500), Alexa Fluor 555 donkey anti-goat IgG H&L (JacksonLab, #705-605-772 147, 1/500). A chromatin staining with DAPI was performed between the two final washes. The 773 sections were oriented and mounted in Mowiol 4-88 medium (Sigma).

774 Image acquisition was performed at the Imaging Core Facility of Strasbourg Biomedical 775 Research Centre (University of Strasbourg, INSERM, PIC-STRA, UMS 38). Fluorescence 776 images were acquired using a Zeiss (LSM 710 NLO) confocal microscope with a 20x Zeiss 777 Plan Apochromat oil-immersion lens (NA 1.40) controlled with the Zen software (ZEN 2012 778 Black edition, Carl Zeiss Microscopy GmbH, Germany). Images were acquired to a resolution 779 of 2048×2048 pixels at subsaturating laser intensities for each channel. To evaluate the 780 percentage of recombined neurons (in the brain) and motoneurons (in the spinal cord), we 781 performed manual counting with FIJI free software(Schindelin et al., 2012). The measurement 782 of the number of neurons in the frontal and motor cortex was made using a homemade macro.

783

784 Western blotting and subcellular fractionation

785 Subcellular fractionation and Western Blotting

Tissues were washed in 1x PBS and lysed in NE-PERNuclear and Cytoplasmic Extraction 786 787 (Thermo Scientific, 78835) according to the manufacturer's instructions. Protein extracts were 788 dosed by BCA Assay (Interchim, UP95424A). Proteins were denatured and SDS page was 789 performed with 30 µg of cytoplasmic proteins and 10 µg of nuclear proteins on Criterion TGX 790 stain-free gel 4-20 % (Biorad, 5678094). Proteins were blotted on nitrocellulose membrane 791 using semi-dry Transblot Turbo system (BioRad, France) and blocked with 10 % non-fat milk 792 during 1 h. Primary antibodies (Rabbit anti-FUS C-ter targeting the NLS (Bethyl, #A300-294 A, 793 1/2000), Rabbit anti-FUS N-Ter (Bethyl, #A-300-293 A, 1/2000), Sheep anti-SOD1 794 (Calbiochem, 574597, 1/1000), Rabbit anti-HDAC1 (Bethyl, #A300-713 A, 1/1000) were 795 incubated overnight at 4 °C in 3 % non-fat milk. Washing was proceeded with washing buffer 796 (Tris pH 7.4 1 M, NaCl 5 M, Tween 20 100 %) and secondary antibodies (anti-rabbit HRP 797 (PARIS, #BI2407,1/5000), anti-sheep HRP (Jackson, #713-035-147, 1/5000); anti-Rat HRP 798 (Rockland, 612-1102, 1/5000) were incubated for 1h30 at room temperature. After successive 799 washes, proteins were visualized with chemiluminescence using ECL Lumina Forte (Millipore, 800 France) and chemiluminescence detector (Bio-Rad, France). Total proteins were detected with 801 stain-free gel capacity (Biorad, 5678094) and used to normalize for protein loading.

802

803 **RT-qPCR**

804 Genomic DNA isolation and PCR

805 Genomic DNA was extracted from hippocampi and lumbar spinal cord using KTT Buffer (Tris 806 HCI, Triton and KCL) with Proteinase K (Sigma, 20mg/mg). DNA was purified using 807 Phenol/Chloroforme (Sigma, P2069) and washed with 70% Ethanol. Polymerase chain 808 reaction (PCR) was performed with MasterMix Tag DNApolymerase (VWR International, Ref. 809 733–1320) and the following primers : LF2 : 5'- CTA-GCC-CAC-CTC-CTA-ATC-CTC-ATC-810 AC-3'; LR2: 5'- CCA-CAC-TTT-AGG-TTA-GTC-ACA-GAT-CAG-C-3' and LXR: 5'- GGA-811 TCC-GCG-GGA-AGT-TCC-TAT-AC-3'. PCR1 correspond to LF2 + LR2 and PCR2 correspond 812 to LF2 + LXR. The following program was used : 5 min 95°C ; (30 s 95°C ; 30 s 62°C ; 30 s 813 72°C) x 34 ; 5 min 72°C). 10 μL of the PCR products were loaded on a 2 % agarose 814 (Euromedex, Ref.D5-E) gel electrophoresis with Low Molecular Weight DNA Ladder (NEB, 815 Ref. N3233L) and stained with ethidium bromide using standard procedures.

816

817 RNA extraction and guantitative PCR

Total RNA was extracted from hippocampi and lumbar spinal cord using TRIzol® reagent (Life 818 819 Technologies). 1 µg of RNA was reverse transcribed with iScript[™] reverse transcription 820 (Biorad, 1,708,841). Quantitative PCR was performed using Sso Advanced Universal SYBR 821 Green Supermix (Bio-Rad 1,725,274) and quantified with Bio-Rad software. Gene expression 822 was normalized by calculating a normalization factor using actin, TBP and pol2 genes 823 according to GeNorm software. Primer sequences are provided in Table XX. 824

825 **RT-PCR**

826 1 μg of RNA was reverse transcribed with iScript[™] reverse transcription (Biorad, 1,708,841). 827 PCR was performed using in 25 µL microtubes with MasterMix Taq DNApolymerase (VWR 828 International, Ref. 733–1320) and the following programs: Intron 6 retention (5 min 95 °C, (30 829 s 95 °C, 30 s 56 °C, 30 s 68 °C) x 30; 5 min 68 °C), Intron 7 retention (5 min 95 °C, (30 s 95 830 °C, 30 s 61 °C, 30 s 68 °C)x 30; 5 min 68 °C), 10 µL of the PCR products were loaded on a 2 831 % agarose (Euromedex, Ref.D5-E) gel electrophoresis with Low Molecular Weight DNA 832 Ladder (NEB, Ref. N3233L) and stained with ethidium bromide using standard procedures. 833 The signal intensity of each of the two bands was guantified individually, and a percentage of 834 intron retention was computed according to this formula: (intensity of Intron + band) / (intensity 835 of Intron + band + intensity of Intron - band) \times 100.

836

837 Single nuclei RNA sequencing

838 10x Genomics Chromium single-cell 3' library construction

839 Cell capture, amplification and library construction on the 10x Genomics Chromium platform 840 were performed according to the manufacturer's publicly available protocol. Briefly, viability 841 was assessed by trypan blue exclusion assay, and cell density was adjusted to 175 cells per 842 microliter. In total, 7,000 cells were then loaded onto a single channel of a 10x Chromium chip 843 for each sample. The 10x Genomics Chromium technology enables 3' digital gene expression 844 profiling of thousands of cells from a single sample by separately indexing each cell's 845 transcriptome. Primers containing (i) an Illumina R1 sequence (read 1 sequencing primer), (ii) 846 a 16-nucleotide 10x Barcode, (iii) a 10-nucleotide UMI, and (iv) a poly-dT primer sequence 847 were released and mixed with cell lysate and Master Mix. Incubation of the GEMs then 848 produced barcoded, full-length cDNA from polyadenylated mRNA. After incubation, the GEMs 849 were broken and the pooled fractions were recovered. Full-length, barcoded cDNA was then 850 amplified by PCR to generate sufficient mass for library construction. Enzymatic fragmentation 851 and size selection were used to optimize the cDNA amplicon size before library construction. 852 R1 (read 1 primer sequence) was added to the molecules during GEM incubation. P5, P7, a 853 sample index and R2 (read 2 primer sequence) were added during library construction via end 854 repair, A-tailing, adaptor ligation and PCR. The final libraries contained the P5 and P7 primers 855 used in Illumina bridge amplification. The described protocol produced Illumina-ready 856 sequencing libraries. A single-cell 3' library comprises standard Illumina paired-end constructs 857 that begin and end with P5 and P7. The single-cell 3' 16-bp 10x Barcode and 10-bp UMI are 858 encoded in read 1, while read 2 is used to sequence the cDNA fragment. Sample index 859 sequences were incorporated as the i7 index read. Read 1 and read 2 are standard Illumina 860 sequencing primer sites used in paired-end sequencing. Sequencing the library produced a 861 standard Illumina BCL data output folder. The BCL data include the paired-end read 1 862 (containing the 16-bp 10x Barcode and 10-bp UMI) and read 2 as well as the sample index in 863 the i7 index read.

864

865 Processing of *Fus*^{ΔNLS} mice single-cell RNA-seg data

Raw FASTQ files were aligned to the pre-mRNA annotated mouse reference genome 866 867 GRCm10. Cell Ranger v.4.0 with default parameters was used to demultiplex and align our 868 barcoded reads with the Ensembl transcriptome annotation (GRCm10). The majority of our 869 downstream analysis was conducted using the R programming language (v.4.0.5 for 870 harmonization and clustering, v.4.1.0 for annotation and downstream visualization) and the 871 RStudio integrated development environment. A recent report suggested that filtering cells with 872 greater than 10% mitochondrial reads is the preferred baseline for human tissue, and that for 873 brain tissue a higher threshold may even be optimal. Thus, a mitochondrial percentage that 874 was the higher of either 10% of reads or the two absolute deviations above the median for 875 mitochondrial reads within the sample was chosen as a threshold. Cells below this threshold 876 with between 500 and 10,000 UMIs were retained for downstream analysis. All ribosomal 877 genes, mitochondrial genes and pseudogenes were removed, as they interfered with the 878 downstream differential gene expression.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

879

880 Processing of ALS patients' single nuclei RNA sequencing.

Raw FASTQ files were downloaded from Pineda et al. (Pineda et al., 2024) and aligned to the pre-mRNA annotated human reference genome GRCh38 using Cell Ranger v4.0 (10x Genomics, Pleasanton CA). Introns were annotated as 'mRNA', and intronic reads were included to quantify expression. Quality control criteria were used as previously described (Bakken et al., 2021) so that for Cv3, criteria were: more than 500 (non-neuronal nuclei) or more than 1,000 (neuronal nuclei) genes were detected and doublet score was less than 0.3.

- 887
- 888 <u>Clustering</u>

889 Nuclei were grouped into transcriptomic cell types using an iterative clustering procedure. 890 Read counts were summed, and log₂-transformed expression was centered and scaled across 891 nuclei. The graph-based clustering approach implemented in Seurat (v.5) was used to cluster 892 our cells. In brief, a k-nearest neighbors graph based on Euclidean distance in our corrected 893 mNN space was calculated and used to derive refined edge weights based on Jaccard 894 similarity. The Louvain algorithm was then applied to iteratively delineate a population structure 895 on our dataset. This was implemented with the FindNeighbors and FindClusters functions in 896 Seurat. A UMAP projection of our dataset was computed with the RunUMAP function for 897 visualization (Figure 1). Differentially expressed genes (DEGs) for a given cluster were identified by using Seurat's FindAllMarkers function with a Wilcox test and comparing each 898 899 cluster with every other cluster under the same subclass, with logfc.threshold set to 0.25 and 900 min.pct set to 0.5. The union of up to 50 genes per cluster with the highest average logFC was 901 used. The average log₂ expression of the DEGs was then used as input for the build dend 902 function from scrattch.hicat to create the dendrograms.

- 903
- 904 Cell type annotation

905 A curated set of known major cell type markers based on Bakken et al., 2021 was used to

annotate individual cells with their expected cell type and assign a confidence score to each

- annotation. For ambiguous subpopulations, we assigned identity based on visually distinct,
- 908 well-defined gene expression domains reproducibly identified by Leiden clustering at multiple
- 909 resolutions. Descriptive labels were determined by the unique co-expression of marker 910 genes identified by Seurat for each subclass.
- 910 911

912 Pseudobulk differential expression analysis

- 913 Cell type-specific pseudo-bulk differential gene expression (DGE) groups were built based on 914 hierarchical clustering and Euclidean distance between each cell subclass. The pseudobulk 915 methods employed the edgeR for analysis of aggregated read counts. Briefly, for cells of a 916 given type, we first aggregated reads across biological replicates, transforming a genes-by-917 cells matrix to a genes-by-replicates matrix using matrix multiplication. For each differential 918 expression cluster, only genes present in at least 10% of cells were retained for analysis. 919 Counts were depth normalized, scaled by library-size, and log₂-transformed. Pseudo-bulk 920 expression profiles were computed by averaging normalized log-counts within each cluster for 921 each unique sample. We used surrogate variable analysis(Leek et al., 2012) (implemented in 922 the SVA R package) to identify and remove sources of unknown variance. We used the quasi-923 likelihood F-test approach (edgeR-QLF) and gene were considered differentially expressed for
- 924 FDR<0.05.
- 925

926 <u>Cross-species consensus co-expression analysis</u>

927 To facilitate comparison across species, mouse gene identifiers were re-annotated with human 928 Ensembl gene orthologs using biomaRt, an R interface with the Biomart database

- 929 (www.biomart.org). Only identifiers that were common to both human and mouse meta-sets
- 930 were retained. A consensus network represents a single network arising from multiple sources

931 of data constructed from the weighted average of correlation matrices from both the human 932 and mouse in this study. By definition, consensus modules are the branches of a clustering 933 tree developed from a consensus gene dissimilarity, comparable to the single-network 934 approach; consensus modules contain genes that are closely related in both networks, i.e., the 935 modules are present in both networks. After scaling the network (consensus scaling 936 guantile=0.2), a threshold power of 14 was chosen (as the smallest threshold resulting in a 937 scale-free R² fit of 0.9). The consensus tree was then built which identified 4 modules for which 938 correlation to phenotype (ALS) and adjusted-pvalue (FDR) were calculated. This approach led 939 to the identification of a final set of 4 modules.

940

941 Violin plot of eigengene expression

For each module and corresponding cell type, the module eigengene was calculated in control and ALS conditions using the moduleEigengenes() function. Comparison across conditions was calculated using a Wilcoxon rank-sum test and considered significant when Bonferroni corrected p-value < 0.05.

946

953

947 ENCODE RNA-binding proteins (RBP) knock-down experiments

A list of 217 RBPs and their counts files were downloaded from the ENCODE consortium (<u>https://www.encodeproject.org/</u>). Counts files for each RBPs were downloaded and normalized to library size and internal controls. A final list of 217 RBPs was used to calculate the eigengene expression of the FUS regulon. Each RBPs was then ranked according to the magnitude of the FUS regulon dysregulation.

954 Olink proteogenomics study cohort

955 Olink proteomic profiling was conducted on blood plasma samples collected from 54,967 UK 956 Biobank participants using the Olink Explore 3072 platform. This platform measured 2,923 957 protein analytes, reflecting 2,941 unique proteins measured across the Olink panels that 958 comprise the 3072 panel. For whole-exome sequencing-based proteogenomic analyses, we 959 analyzed the 52,217 samples with available paired-exome sequence data. We identified the 960 participants with European genetic ancestry based on HapMap projection. We performed finer-961 scale ancestry pruning of these individuals, retaining those within 4 s.d. from the mean across 962 the first four principal components, resulting in a final cohort of 46,327 individuals for the 963 proteogenomic analyses. Finally, we built metadata on neurodegenerative diseases diagnosed 964 after enrollment (AD, PD, ALS, VaD, AD) and carriers' status of FBX016 PTV (FBX016). We 965 filtered individuals to have age-and sex matched controls for each disease resulting in a final 966 cohort of 24,557 individuals. To ensures a minimum number of observations per group, 967 proteins with a high fraction of missing values (>75% of participants) were excluded from the 968 regression analysis. In addition, groupwise outlier removal of protein measurements ($\pm 1.5 \times$ 969 IQR) was performed before regression analysis because the presence of outliers can severely 970 affect the resulting test statistics, potentially increasing the rate of false negatives in the initial 971 biomarker discovery phase. Linear regression adjusted for age and sex, was performed for 972 each protein and disease. Genome-wide significant association was set at Bonferroni 973 corrected p-value < 0.05 / 2,941.

974

975 Brain MRI UK Biobank data acquisition

976 UK Biobank brain imaging has been described as a resource (Miller et al., 2016), where the 977 reader can find a number of examples describing how it can be accessed and used for 978 research. Three dedicated imaging centers are equipped with identical scanners (3T Siemens 979 Skyra, software VD13) for brain imaging scanning using the standard Siemens 32-channel 980 receive head coil. The brain MRI protocol is performed using a 3 Tesla Siemens Skyra scanner 981 (Siemens Healthineers, Erlangen, Germany) with VD13 software and a 32-channel head coil. 982 The protocol includes three structural MRI scans; T1, T2 fluid attenuation inversion recovery 983 (FLAIR) and susceptibility-weighted MRI (swMRI), as well as diffusion MRI (dMRI) and resting

984 and task functional MRI (fMRI). T1 scans allow precise volumetric measures of the whole brain, 985 as well as specific cortical and subcortical regions. An automated processing pipeline for brain 986 image analysis and quality control was established for UKB at the University of Oxford's 987 Wellcome Centre for Integrative Neuroimaging (WIN/FMRIB). This pipeline is primarily based 988 around FSL (FMRIB's Software Library), and other packages such as FreeSurfer. When 989 acquired at the imaging center, the images are reconstructed from k-space on the scanner 990 computer and saved initially as DICOM files. The processing pipeline then converts these files 991 to the NIFTI format and undertakes pre-processing (e.g., correcting for head motion and other 992 artefacts) as well as automated quality control that identifies issue with the equipment (e.g., 993 coil failure) and artefacts specific to the participant or scanning session (e.g., excessive head 994 movement). The NIFTI files for the T1 are provided to researchers, as these are suitably 995 "defaced" to remove the possibility of re-identification of any individual participant. The pipeline 996 also automatically generates thousands of IDPs, such as regional grey matter volume from T1 997 scans, fractional anisotropy, axial diffusivity and mean diffusivity measures from dMRI scans. 998 These IDPs have been made available to researchers with authorized access and were used 999 for GWAS association with FBXO16 carriers' status.

1000

1001 Grey matter volume, area and thickness analysis in FBX016 PTV carriers

1002 Grey matter volumes, area and thickness were produced using the recon-all script, in cross-1003 sectional mode, of FreeSurfer version 5.3 (Fischl, 2012) on each T1-weighted scan. The 1004 standard pre-processing steps of the FreeSurfer image analysis suite were first implemented, 1005 including removal of non-brain tissue, segmentation of the subcortical white matter and deep 1006 grey matter structures, intensity normalization, tessellation of the grey matter-white matter 1007 boundary, and automated topology correction. Following guality control steps for segmentation 1008 accuracy, overall volumes of cortical structures and total intracranial volume estimates (eTIV) 1009 were retrieved from each subject. A dual pipeline was implemented exploring cortical thickness 1010 alterations and morphometric changes using voxel-based morphometry (VBM). Following pre-1011 processing and cortical segmentation in FreeSurfer, average cortical thickness, volume and 1012 area values have been retrieved from 34 cortical regions in each hemisphere separately as 1013 per the Desikan-Killiany atlas(Desikan et al., 2006). Cortical thickness values in the following 1014 lobes and corresponding subregions regions were appraised, Frontal lobe (13 ROIs): Superior 1015 Frontal, Rostral and Caudal Middle Frontal, Pars Opercularis, Pars Triangularis, and Pars 1016 Orbitalis, Lateral and Medial Orbitofrontal, Precentral, Paracentral, Frontal Pole, Rostral 1017 Anterior cingulate, Caudal Anterior cingulate, Parietal lobe (7 ROIs): Superior Parietal, Inferior 1018 Parietal, Supramarginal, Postcentral, Precuneus, Posterior cingulate, cingulate isthmus, 1019 Temporal lobe (9 ROIs): Superior, Middle, and Inferior Temporal, Banks of the Superior 1020 Temporal Sulcus. Fusiform, Transverse Temporal. Entorhinal, Temporal Pole. Parahippocampal, Occipital lobe (4 ROIs): lateral Occipital, Lingual, Cuneus, Pericalcarine, 1021 1022 and the Insula (1 ROI). In addition to cortical thickness analyses, voxel-based morphometry 1023 was also performed to evaluate anatomical patterns of signal intensity reductions in mutation 1024 carriers. Regional effects of FBXO16 PTV status on cortical thickness, area and volume were 1025 tested by general linear models (GLM) across the entire cortex controlling for age and sex. 1026 Permutation-based non-parametric inference and the threshold-free cluster enhancement 1027 (TFCE) approach were used to test for differences between study groups and significance was 1028 set at FDR < 0.05

1029

1030 Connectometry

1031 For DTI preprocessing of brain MRI, the DSI Studio software (version May 2024, http://dsi-1032 studio.labsolver.org) was utilized. This program, equipped with open-source images, 1033 addressed eddy current and phase distortion artefacts, generated a mask through 1034 thresholding, smoothing, and defragmentation, and underwent a quality control step for DTI. 1035 Subsequently, diffusion data were reconstructed using the DTI method and generalized g-1036 sampling imaging (GQI) with a diffusion sampling length ratio of 1.25 (Yeh et al., 2010). The

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

1037 connectometry analysis incorporated DTI-based metrics, including FA, MD, AD, and RD 1038 values, and GQI-based QA values, extracted as the local connectome fingerprint (Yeh et al., 1039 2016) When correlated with the apnea-hypopnea index (AHI), a representative measure of 1040 OSA severity, diffusion MRI connectometry demonstrated changes in FA, MD, AD, RD, and 1041 QA values. Non-parametric Spearman partial correlation, removing the effects of sex and age 1042 via a multiple regression model, was used to derive these correlations. A T-score threshold of 1043 2.5 guided deterministic fiber tracking for correlational tractography.

1044

LD-score regression and partitioned heritability for ALS 1045

1046 We used the summary association statistics from the latest GWAS of ALS (van Rheenen et 1047 al., 2021). FUS regulon genes were mapped on single nuclei ATACseg data on major brain 1048 cell types (Corces et al., 2020) leading to 17,280 cell type-specific ATAC peaks associated 1049 with the FUS regulon (n=738 genes). As a positive control, we used the latest ALS GWAS and 1050 extracted SNP with suggestive association with ALS (p<5.10⁻⁰⁶). Each SNP were mapped to 1051 the snATACseq using the same procedure leading to 13,278 ATAC peaks used as input to 1052 ALS-GWAS LDSC analysis. As a negative control, we randomly selected 15,000 ATAC peaks 1053 in a pool of 252,276 non-overlapping peaks across 6 major brain cell types. For each of the 1054 above-created sets, we ran S-LDSC (Finucane et al., 2018) to generate the LD score of each 1055 variant in each annotation using the same procedure. Regression SNPs, that are used by S-1056 LDSC to estimate τ from marginal association statistics, were obtained from the HapMap 1057 Project phase (International HapMap, 2003). Using the LD score for each annotation and the 1058 marginal statistics obtained from the trait phenotypes (GWAS-ALS), we computed the 1059 enrichment and calculated the p-value for each annotation(Finucane et al., 2018).

1060

1061 GWAS of ALS-bi/ci in the AnswerALS cohort

Whole genome sequencing from 631 ALS patients from the AnswerALS cohorts used were 1062 preprocessed for GWAS analysis (Baxi et al., 2022). Duplicate individuals were removed (king-1063 1064 cutoff = 0.084). Population structure was assessed by projecting 1000 G principal components 1065 (PCs) and outliers from the European ancestry population were removed (>4SD on PC1-4). 1066 In total, 546 ALS cases passed quality check analysis. WGS SNPs variants were mapped to 1067 genes using the SNP-to-Gene approach as described in MAGMA(de Leeuw et al., 2015) 1068 leading to a final set of 143,188 variants used for GWAS analysis. After quality control, a null 1069 logistic mixed model was fitted using PLINK with principal component (PC)1-PC10, sex, age 1070 at onset and APOE genotype as covariates. To assess any residual confounding due to 1071 population stratification and artificial structure in the data, we calculated the LDSC intercept 1072 using SNP LD scores calculated in the HapMap3 CEU population. Genome-wide significance 1073 was set at 5.10⁻⁰⁷.

1074

1075 **Statistics**

1076 Values from each animal were averaged for each genotype group and data are expressed as 1077 mean ± standard error of the mean (SEM). Statistical analysis was performed using the 1078 GraphPad Prism 8 software with a significant threshold set at p < 0.05. Analysis of variance 1079 (ANOVA) was used because it was justified by the independence and normality of results and 1080 the equality of variances. Details of the analyses are systematically given in the figure legends. 1081 Normality and homoscedasticity were both assessed prior to analysis using Shapiro-Wilk and 1082 Bartlett's test, respectively. Statistical analysis of two groups were performed using 1083 independent Student's t-tests with Statsmodels package

- 1084
- 1085

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

1086 **Resource availability**

- 1087 All snRNAseq datasets have been deposited on GEO.
- 1088 *Fus*^{exon15} mice are available upon request to the corresponding authors.
- 1089

1090 Acknowledgements

1091 The authors would like to thank the technicians of the animal facilities, namely Célian Pitard, 1092 Christiane Rieger and Claudia Spielmann, for their care of the mice. We are grateful to 1093 PICSTRA Imaging platform (UMS38, CRBS) and PEFRE animal facility platform (UMS38, 1094 CRBS for technical assistance and support. We acknowledge all persons involved in the 1095 mouse generation project at the ICS (Strasbourg, France) for their assistance with project 1096 design and data analysis. This work was supported in part by the Intramural Research Program 1097 of the National Institutes of Health, the National Institute on Aging (1ZIAAG000933). This work 1098 was funded by Agence Nationale de la Recherche (ANR-16-CE92-0031, ANR-19-CE17-0016, 1099 ANR-20-CE17-0008, ANR-21-CE17-0039, ANR-24-CE37-4064), by the Interdisciplinary 1100 Thematic Institute NeuroStra, as part of the ITI 2021-2028 (Idex Unistra ANR-10-IDEX-0002, 1101 ANR-20-SFRI-0012) by Fondation Bettencourt (Coup d'élan 2019 to LD), Fondation pour la 1102 recherche médicale (FRM, DEQ20180339179), Axa Research Funds (rare diseases award 1103 2019, to LD), Association Francaise de Recherche sur la sclérose latérale amyotrophique, the 1104 Association Française contre les Myopathies (AFM-Téléthon, #23646, #28944)). LD is USIAS 1105 fellow 2019).

1106

1107 **Author contributions**

1108 Mouse breeding genotyping were performed by C.D.T., S.D. and R.C. Mouse tissues were 1109 processed by R.C., F.L. and A.B. Histological analysis in mice was conducted by R.C., F.L., 1110 A.B., and P.K. The Fus mouse model generation was conducted by M-C.B. Behavioral tests 1111 were conducted by R.C., F.L., A.B. and C.D. while the analysis was performed by R.C and 1112 S.D. EEG surgery and analysis were performed by S.J.G. and G.S.L. Single-nucleus RNA 1113 sequencing analysis, cross-species integration, genetic analyses, and UK Biobank data mining 1114 were conducted by S.M. Human Pathology was performed by F.M.W. and J.M.G. SnRNAseg 1115 of ALS and ALS-ci patients was performed and analyzed by S.M., C.G.R., C.A.J. and H.P.. 1116 B.T., A.C., R.R. and J.S. contributed with clinical and genetic data as well as research tools. 1117 Funding was secured by R.C. and L.D. The work was conceptualized, coordinated and 1118 supervised by R.C., LD and SM. The manuscript was written by R.C, L.D. and S.M.

1119

1120 **Declaration of interests**

BJT has a patent pending (U.S. Patent Application No. 63/717,807) on the diagnostic testing for ALS based on a proteomic panel. BJT holds patents on the clinical testing and therapeutic intervention for the hexanucleotide repeat expansion of *C9orf72*. BJT receives research support from Cerevel Therapeutics.

1125

1126 Supplemental information

- 1127 Document with Figures S1–S8.
- 1128 Tables S1 & S2.
- 1129

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

1130 References

- 1131
- 1132 Abrahams, S. (2023). Neuropsychological impairment in amyotrophic lateral sclerosis-1133 frontotemporal spectrum disorder. Nat Rev Neurol 19, 655-667.
- 1134 Aguzzoli, C.S., Battista, P., Hadad, R., Ferreira Felloni Borges, Y., Schilling, L.P., and Miller, 1135 B.L. (2022). Very early-onset behavioral variant frontotemporal dementia in a patient 1136 with a variant of uncertain significance of a FUS gene mutation. Neurocase 28, 403-409.
- 1137 Bakken, T.E., Jorstad, N.L., Hu, Q., Lake, B.B., Tian, W., Kalmbach, B.E., Crow, M., Hodge,
- 1138 R.D., Krienen, F.M., Sorensen, S.A., et al. (2021). Comparative cellular analysis of motor 1139 cortex in human, marmoset and mouse. Nature 598, 111-119.
- 1140 Bampton, A., McHutchison, C., Talbot, K., Benatar, M., Thompson, A.G., and Turner, M.R. 1141 (2024). The Basis of Cognitive and Behavioral Dysfunction in Amyotrophic Lateral 1142 Sclerosis. Brain Behav 14. e70115.
- 1143 Baxi, E.G., Thompson, T., Li, J., Kaye, J.A., Lim, R.G., Wu, J., Ramamoorthy, D., Lima, L., 1144 Vaibhav, V., Matlock, A., et al. (2022). Answer ALS, a large-scale resource for sporadic 1145 and familial ALS combining clinical and multi-omics data from induced pluripotent cell 1146 lines. Nat Neurosci 25, 226-237.
- 1147 Bellmann, J., Monette, A., Tripathy, V., Sojka, A., Abo-Rady, M., Janosh, A., Bhatnagar, R., 1148 Bickle, M., Mouland, A.J., and Sterneckert, J. (2019). Viral Infections Exacerbate FUS-1149 ALS Phenotypes in iPSC-Derived Spinal Neurons in a Virus Species-Specific Manner. 1150 Frontiers in cellular neuroscience 13, 480.
- 1151 Bosco, D.A., Lemay, N., Ko, H.K., Zhou, H., Burke, C., Kwiatkowski, T.J., Jr., Sapp, P., 1152 McKenna-Yasek, D., Brown, R.H., Jr., and Hayward, L.J. (2010). Mutant FUS proteins 1153 that cause amyotrophic lateral sclerosis incorporate into stress granules. Hum Mol 1154 Genet 19, 4160-4175.
- 1155 Broustal, O., Camuzat, A., Guillot-Noel, L., Guy, N., Millecamps, S., Deffond, D., Lacomblez, 1156 L., Golfier, V., Hannequin, D., Salachas, F., et al. (2010). FUS mutations in 1157 frontotemporal lobar degeneration with amyotrophic lateral sclerosis. J Alzheimers Dis 1158 22, 765-769.
- Brown, A.L., Wilkins, O.G., Keuss, M.J., Hill, S.E., Zanovello, M., Lee, W.C., Bampton, A., 1159 Lee, F.C.Y., Masino, L., Qi, Y.A., et al. (2022). TDP-43 loss and ALS-risk SNPs drive 1160 1161 mis-splicing and depletion of UNC13A. Nature.
- 1162 Brown, R.H., Jr., and Al-Chalabi, A. (2017). Amyotrophic Lateral Sclerosis. N Engl J Med 1163 377. 162-172.
- 1164 Bulik-Sullivan, B.K., Loh, P.R., Finucane, H.K., Ripke, S., Yang, J., Schizophrenia Working 1165 Group of the Psychiatric Genomics, C., Patterson, N., Daly, M.J., Price, A.L., and Neale, 1166 B.M. (2015). LD Score regression distinguishes confounding from polygenicity in 1167 genome-wide association studies. Nat Genet 47, 291-295.
- 1168 Carlson, C.G., Rutter, J., Bledsoe, C., Singh, R., Hoff, H., Bruemmer, K., Sesti, J., Gatti, F., 1169 Berge, J., and McCarthy, L. (2010). A simple protocol for assessing inter-trial and inter-1170 examiner reliability for two noninvasive measures of limb muscle strength. J Neurosci 1171 Methods 186, 226-230.
- 1172 Caroni, P. (1997). Overexpression of growth-associated proteins in the neurons of adult 1173 transgenic mice. J Neurosci Methods 71, 3-9.
- 1174 Chen, K., Gao, T., Liu, Y., Zhu, K., Wang, T., and Zeng, P. (2024). Identifying risk loci for 1175 FTD and shared genetic component with ALS: A large-scale multitrait association 1176 analysis. Neurobiol Aging 134, 28-39.
- 1177 Cheng, Y.Y., Chou, Y.T., Lai, F.J., Jan, M.S., Chang, T.H., Jou, I.M., Chen, P.S., Lo, J.Y.,
- 1178 Huang, S.S., Chang, N.S., et al. (2020). Wwox deficiency leads to neurodevelopmental 1179 and degenerative neuropathies and glycogen synthase kinase 3beta-mediated epileptic 1180 seizure activity in mice. Acta Neuropathol Commun 8, 6.
- 1181 Corces, M.R., Shcherbina, A., Kundu, S., Gloudemans, M.J., Fresard, L., Granja, J.M.,
- 1182 Louie, B.H., Eulalio, T., Shams, S., Bagdatli, S.T., et al. (2020). Single-cell epigenomic

1183 analyses implicate candidate causal variants at inherited risk loci for Alzheimer's and 1184 Parkinson's diseases. Nat Genet 52, 1158-1168.

- 1185 D'Anna, L., Mesulam, M.M., Thiebaut de Schotten, M., Dell'Acqua, F., Murphy, D., Wieneke, 1186 C., Martersteck, A., Cobia, D., Rogalski, E., and Catani, M. (2016). Frontotemporal 1187 networks and behavioral symptoms in primary progressive aphasia. Neurology 86, 1393-1188 1399.
- 1189 De Decker, M., Zelina, P., Moens, T.G., Beckers, J., Contardo, M., Dittlau, K.S., Van Schoor, 1190 E., Ronisz, A., Eggermont, K., Moisse, M., et al. (2025). C21ORF2 mutations point 1191 towards primary cilia dysfunction in amyotrophic lateral sclerosis. Brain 148, 803-816.
- de Leeuw, C.A., Mooij, J.M., Heskes, T., and Posthuma, D. (2015). MAGMA: generalized 1192 1193 gene-set analysis of GWAS data. PLoS Comput Biol 11, e1004219.
- 1194 Deacon, R.M. (2006). Assessing nest building in mice. Nature protocols 1, 1117-1119.
- 1195 Desikan, R.S., Segonne, F., Fischl, B., Quinn, B.T., Dickerson, B.C., Blacker, D., Buckner, 1196 R.L., Dale, A.M., Maguire, R.P., Hyman, B.T., et al. (2006). An automated labeling 1197 system for subdividing the human cerebral cortex on MRI scans into gyral based regions 1198 of interest. Neuroimage 31, 968-980.
- 1199 Diekstra, F.P., Van Deerlin, V.M., van Swieten, J.C., Al-Chalabi, A., Ludolph, A.C., 1200 Weishaupt, J.H., Hardiman, O., Landers, J.E., Brown, R.H., Jr., van Es, M.A., et al. 1201 (2014). C9orf72 and UNC13A are shared risk loci for amyotrophic lateral sclerosis and
- 1202 frontotemporal dementia: a genome-wide meta-analysis. Ann Neurol 76, 120-133. 1203 Dormann, D., Rodde, R., Edbauer, D., Bentmann, E., Fischer, I., Hruscha, A., Than, M.E., 1204 Mackenzie, I.R., Capell, A., Schmid, B., et al. (2010). ALS-associated fused in sarcoma 1205 (FUS) mutations disrupt Transportin-mediated nuclear import. EMBO J 29, 2841-2857.
- Dugan, A.J., Nelson, P.T., Katsumata, Y., Shade, L.M.P., Teylan, M.A., Boehme, K.L., 1206 Mukherjee, S., Kauwe, J.S.K., Hohman, T.J., Schneider, J.A., et al. (2022). Association 1207 1208 between WWOX/MAF variants and dementia-related neuropathologic endophenotypes. 1209 Neurobiol Aging 111, 95-106.
- 1210 Dulski, J., Strongosky, A.J., Al-Shaikh, R.H., and Wszolek, Z.K. (2023). Expanding the 1211 spectrum of KIF5A mutations-case report of a large kindred with familial ALS and 1212 overlapping syndrome. Amyotrophic lateral sclerosis & frontotemporal degeneration 24. 1213 347-350.
- 1214 Elahi, F.M., Marx, G., Cobigo, Y., Staffaroni, A.M., Kornak, J., Tosun, D., Boxer, A.L., 1215 Kramer, J.H., Miller, B.L., and Rosen, H.J. (2017). Longitudinal white matter change in 1216 frontotemporal dementia subtypes and sporadic late onset Alzheimer's disease. 1217 Neuroimage Clin 16, 595-603.
- 1218 Feil, R., Wagner, J., Metzger, D., and Chambon, P. (1997). Regulation of Cre recombinase 1219 activity by mutated estrogen receptor ligand-binding domains. Biochem Biophys Res 1220 Commun 237, 752-757.
- 1221 Finucane, H.K., Reshef, Y.A., Anttila, V., Slowikowski, K., Gusev, A., Byrnes, A., Gazal, S., 1222 Loh, P.R., Lareau, C., Shoresh, N., et al. (2018). Heritability enrichment of specifically 1223 expressed genes identifies disease-relevant tissues and cell types. Nat Genet 50, 621-1224 629.
- 1225 Fischl, B. (2012). FreeSurfer. Neuroimage 62, 774-781.
- 1226 Forrest, S.L., and Kovacs, G.G. (2024). Current concepts and molecular pathology of 1227 neurodegenerative diseases. Pathology.
- 1228 Gao, C., Gu, J., Zhang, H., Jiang, K., Tang, L., Liu, R., Zhang, L., Zhang, P., Liu, C., Dai, B., 1229 et al. (2022). Hyperosmotic-stress-induced liquid-liquid phase separation of ALS-related 1230 proteins in the nucleus. Cell Rep 40, 111086.
- 1231 Gascon, E., Lynch, K., Ruan, H., Almeida, S., Verheyden, J.M., Seeley, W.W., Dickson, 1232 D.W., Petrucelli, L., Sun, D., Jiao, J., et al. (2014). Alterations in microRNA-124 and 1233 AMPA receptors contribute to social behavioral deficits in frontotemporal dementia. Nat 1234 Med 20, 1444-1451.

- perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .
- 1235 Goldstein, O., Inbar, T., Kedmi, M., Gana-Weisz, M., Abramovich, B., Orr-Urtreger, A., and 1236 Drory, V.E. (2022). FUS-P525L Juvenile Amyotrophic Lateral Sclerosis and Intellectual 1237 Disability: Evidence for Association and Oligogenic Inheritance. Neurol Genet 8, 1238 e200009.
- 1239 Goutman, S.A., Hardiman, O., Al-Chalabi, A., Chio, A., Savelieff, M.G., Kiernan, M.C., and 1240 Feldman, E.L. (2022a). Emerging insights into the complex genetics and 1241 pathophysiology of amyotrophic lateral sclerosis. Lancet Neurol.
- 1242 Goutman, S.A., Hardiman, O., Al-Chalabi, A., Chio, A., Savelieff, M.G., Kiernan, M.C., and 1243 Feldman, E.L. (2022b). Recent advances in the diagnosis and prognosis of amyotrophic 1244 lateral sclerosis. Lancet Neurol.
- 1245 Grassano, M., Brodini, G., De Marco, G., Casale, F., Fuda, G., Salamone, P., Brunetti, M., 1246 Sbaiz, L., Gallone, S., Cugnasco, P., et al. (2022). Phenotype Analysis of Fused in 1247 Sarcoma Mutations in Amyotrophic Lateral Sclerosis. Neurol Genet 8, e200011.
- 1248 Gregory, J.M., McDade, K., Bak, T.H., Pal, S., Chandran, S., Smith, C., and Abrahams, S. 1249 (2020). Executive, language and fluency dysfunction are markers of localised TDP-43 1250 cerebral pathology in non-demented ALS. J Neurol Neurosurg Psychiatry 91, 149-157.
- 1251 Guillot, S.J. (2023). EEVop (sjg2203/EEVop: GitHub, Zenodo).
- 1252 Guillot, S.J., Lang, C., Simonot, M., Beckett, D., Lule, D., Balz, L.T., Knehr, A., Stuart-Lopez, 1253 G., Vercruysse, P., Dieterle, S., et al. (2025). Early-onset sleep alterations found in 1254 patients with amyotrophic lateral sclerosis are ameliorated by orexin antagonist in mouse 1255 models. Sci Transl Med 17, eadm7580.
- 1256 Guo, Y., You, J., Zhang, Y., Liu, W.S., Huang, Y.Y., Zhang, Y.R., Zhang, W., Dong, Q., 1257 Feng, J.F., Cheng, W., et al. (2024). Plasma proteomic profiles predict future dementia 1258 in healthy adults. Nat Aging 4. 247-260.
- 1259 Hirayanagi, K., Sato, M., Furuta, N., Makioka, K., and Ikeda, Y. (2016). Juvenile-onset 1260 Sporadic Amyotrophic Lateral Sclerosis with a Frameshift FUS Gene Mutation 1261 Presenting Unique Neuroradiological Findings and Cognitive Impairment. Intern Med 55, 1262 689-693.
- 1263 Hock, E.-M., Maniecka, Z., Hruska-Plochan, M., Reber, S., Laferriere, F., Sahadevan M K, 1264 S., Ederle, H., Gittings, L., Pelkmans, L., Dupuis, L., et al. (2018). Hypertonic Stress Causes Cytoplasmic Translocation of Neuronal, but Not Astrocytic, FUS due to Impaired 1265 1266 Transportin Function. Cell reports 24, 987-1000.e1007.
- 1267 Humphrey, J., Birsa, N., Milioto, C., McLaughlin, M., Ule, A.M., Robaldo, D., Eberle, A.B., 1268 Krauchi, R., Bentham, M., Brown, A.L., et al. (2020). FUS ALS-causative mutations 1269 impair FUS autoregulation and splicing factor networks through intron retention. Nucleic 1270 Acids Res 48, 6889-6905.
- 1271 International HapMap, C. (2003). The International HapMap Project. Nature 426, 789-796.
- 1272 Irwin, D.J., Grossman, M., Weintraub, D., Hurtig, H.I., Duda, J.E., Xie, S.X., Lee, E.B., Van 1273 Deerlin, V.M., Lopez, O.L., Kofler, J.K., et al. (2017). Neuropathological and genetic 1274 correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. 1275 Lancet Neurol 16, 55-65.
- 1276 Isingrini, E., Camus, V., Le Guisquet, A.M., Pingaud, M., Devers, S., and Belzung, C. (2010). 1277 Association between repeated unpredictable chronic mild stress (UCMS) procedures 1278 with a high fat diet: a model of fluoxetine resistance in mice. PLoS One 5, e10404.
- 1279 James, B.D., Wilson, R.S., Boyle, P.A., Trojanowski, J.Q., Bennett, D.A., and Schneider, J.A. 1280 (2016). TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia. Brain 1281 139. 2983-2993.
- 1282 Jeong, Y.H., Ling, J.P., Lin, S.Z., Donde, A.N., Braunstein, K.E., Majounie, E., Traynor, B.J., 1283 LaClair, K.D., Lloyd, T.E., and Wong, P.C. (2017). Tdp-43 cryptic exons are highly 1284 variable between cell types. Mol Neurodegener 12, 13.
- 1285 Karanth, S., Nelson, P.T., Katsumata, Y., Kryscio, R.J., Schmitt, F.A., Fardo, D.W.,
- 1286 Cykowski, M.D., Jicha, G.A., Van Eldik, L.J., and Abner, E.L. (2020). Prevalence and

1287 Clinical Phenotype of Quadruple Misfolded Proteins in Older Adults. JAMA Neurol 77, 1288 1299-1307. 1289 Katisko, K., Cajanus, A., Huber, N., Jaaskelainen, O., Kokkola, T., Karkkainen, V., Rostalski, 1290 H., Hartikainen, P., Koivisto, A.M., Hannonen, S., et al. (2021). GFAP as a biomarker in 1291 frontotemporal dementia and primary psychiatric disorders: diagnostic and prognostic 1292 performance. J Neurol Neurosurg Psychiatry 92, 1305-1312. 1293 Katsumata, Y., Abner, E.L., Karanth, S., Teylan, M.A., Mock, C.N., Cykowski, M.D., Lee, 1294 E.B., Boehme, K.L., Mukherjee, S., Kauwe, J.S.K., et al. (2020). Distinct 1295 clinicopathologic clusters of persons with TDP-43 proteinopathy. Acta Neuropathol 140. 1296 659-674. 1297 Khan, M., Muzumdar, D., and Shiras, A. (2019). Attenuation of Tumor Suppressive Function 1298 of FBXO16 Ubiquitin Ligase Activates Wnt Signaling In Glioblastoma. Neoplasia 21, 1299 106-116. 1300 Kosla, K., Pluciennik, E., Styczen-Binkowska, E., Nowakowska, M., Orzechowska, M., and 1301 Bednarek, A.K. (2019). The WWOX Gene Influences Cellular Pathways in the Neuronal 1302 Differentiation of Human Neural Progenitor Cells. Frontiers in cellular neuroscience 13, 1303 391. 1304 Kunkle, B.W., Grenier-Boley, B., Sims, R., Bis, J.C., Damotte, V., Naj, A.C., Boland, A., 1305 Vronskaya, M., van der Lee, S.J., Amlie-Wolf, A., et al. (2019). Genetic meta-analysis of 1306 diagnosed Alzheimer's disease identifies new risk loci and implicates Abeta, tau, 1307 immunity and lipid processing. Nat Genet 51, 414-430. 1308 Kwiatkowski, T.J., Jr., Bosco, D.A., Leclerc, A.L., Tamrazian, E., Vanderburg, C.R., Russ, C., 1309 Davis, A., Gilchrist, J., Kasarskis, E.J., Munsat, T., et al. (2009). Mutations in the 1310 FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 1311 323, 1205-1208. 1312 Lagier-Tourenne, C., Polymenidou, M., and Cleveland, D.W. (2010). TDP-43 and FUS/TLS: 1313 emerging roles in RNA processing and neurodegeneration. Hum Mol Genet 19, R46-64. 1314 Lagier-Tourenne, C., Polymenidou, M., Hutt, K.R., Vu, A.Q., Baughn, M., Huelga, S.C., 1315 Clutario, K.M., Ling, S.C., Liang, T.Y., Mazur, C., et al. (2012). Divergent roles of ALS-1316 linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. Nat 1317 Neurosci 15, 1488-1497. 1318 Lanteri, P., Meola, I., Canosa, A., De Marco, G., Lomartire, A., Rinaudo, M.T., Albamonte, E., 1319 Sansone, V.A., Lunetta, C., Manera, U., et al. (2021). The heterozygous deletion 1320 c.1509 1510delAG in exon 14 of FUS causes an aggressive childhood-onset ALS with 1321 cognitive impairment. Neurobiol Aging 103, 130 e131-130 e137. 1322 Leek, J.T., Johnson, W.E., Parker, H.S., Jaffe, A.E., and Storey, J.D. (2012). The sva 1323 package for removing batch effects and other unwanted variation in high-throughput 1324 experiments. Bioinformatics 28, 882-883. 1325 Lin, Y.C., Kumar, M.S., Ramesh, N., Anderson, E.N., Nguyen, A.T., Kim, B., Cheung, S., 1326 McDonough, J.A., Skarnes, W.C., Lopez-Gonzalez, R., et al. (2021). Interactions 1327 between ALS-linked FUS and nucleoporins are associated with defects in the 1328 nucleocytoplasmic transport pathway. Nat Neurosci. 1329 Ling, J.P., Pletnikova, O., Troncoso, J.C., and Wong, P.C. (2015). TDP-43 repression of 1330 nonconserved cryptic exons is compromised in ALS-FTD. Science 349, 650-655. 1331 Littlejohns, T.J., Holliday, J., Gibson, L.M., Garratt, S., Oesingmann, N., Alfaro-Almagro, F., 1332 Bell, J.D., Boultwood, C., Collins, R., Conroy, M.C., et al. (2020). The UK Biobank 1333 imaging enhancement of 100,000 participants: rationale, data collection, management 1334 and future directions. Nat Commun 11, 2624. 1335 Liu, E.Y., Russ, J., Cali, C.P., Phan, J.M., Amlie-Wolf, A., and Lee, E.B. (2019). Loss of 1336 Nuclear TDP-43 Is Associated with Decondensation of LINE Retrotransposons. Cell Rep 1337 27, 1409-1421 e1406. 1338 Liu, G., Peng, J., Liao, Z., Locascio, J.J., Corvol, J.C., Zhu, F., Dong, X., Maple-Grodem, J., 1339 Campbell, M.C., Elbaz, A., et al. (2021). Genome-wide survival study identifies a novel

- 1340 synaptic locus and polygenic score for cognitive progression in Parkinson's disease. Nat 1341 Genet 53, 787-793.
- 1342 Lueptow, L.M. (2017). Novel Object Recognition Test for the Investigation of Learning and 1343 Memory in Mice. J Vis Exp.
- 1344 Luisier, R., Tyzack, G.E., Hall, C.E., Mitchell, J.S., Devine, H., Taha, D.M., Malik, B., Meyer, 1345 I., Greensmith, L., Newcombe, J., et al. (2018). Intron retention and nuclear loss of 1346 SFPQ are molecular hallmarks of ALS. Nat Commun 9, 2010.
- 1347 Ma, X.R., Prudencio, M., Koike, Y., Vatsavayai, S.C., Kim, G., Harbinski, F., Briner, A., 1348 Rodriguez, C.M., Guo, C., Akiyama, T., et al. (2022). TDP-43 represses cryptic exon 1349 inclusion in the FTD-ALS gene UNC13A. Nature.
- 1350 Mackenzie, I.R., Ansorge, O., Strong, M., Bilbao, J., Zinman, L., Ang, L.C., Baker, M., 1351 Stewart, H., Eisen, A., Rademakers, R., et al. (2011a). Pathological heterogeneity in 1352 amyotrophic lateral sclerosis with FUS mutations: two distinct patterns correlating with 1353 disease severity and mutation. Acta Neuropathol 122, 87-98.
- 1354 Mackenzie, I.R., Munoz, D.G., Kusaka, H., Yokota, O., Ishihara, K., Roeber, S., Kretzschmar, 1355 H.A., Cairns, N.J., and Neumann, M. (2011b). Distinct pathological subtypes of FTLD-1356 FUS. Acta Neuropathol 121, 207-218.
- 1357 Mahoney, C.J., Simpson, I.J., Nicholas, J.M., Fletcher, P.D., Downey, L.E., Golden, H.L., 1358 Clark, C.N., Schmitz, N., Rohrer, J.D., Schott, J.M., et al. (2015). Longitudinal diffusion 1359 tensor imaging in frontotemporal dementia. Ann Neurol 77, 33-46.
- 1360 Maldonado-Diaz, C., Hiya, S., Yokoda, R.T., Farrell, K., Marx, G.A., Kauffman, J., Daoud, 1361 E.V., Gonzales, M.M., Parker, A.S., Canbeldek, L., et al. (2024). Disentangling and 1362 quantifying the relative cognitive impact of concurrent mixed neurodegenerative 1363 pathologies. Acta Neuropathol 147.58.
- Mallaret, M., Synofzik, M., Lee, J., Sagum, C.A., Mahajnah, M., Sharkia, R., Drouot, N., 1364 1365 Renaud, M., Klein, F.A., Anheim, M., et al. (2014). The tumour suppressor gene WWOX 1366 is mutated in autosomal recessive cerebellar ataxia with epilepsy and mental retardation. 1367 Brain 137, 411-419.
- 1368 Megat, S., Mora, N., Sanogo, J., Roman, O., Catanese, A., Alami, N.O., Freischmidt, A., 1369 Mingaj, X., De Calbiac, H., Muratet, F., et al. (2023). Integrative genetic analysis 1370 illuminates ALS heritability and identifies risk genes. Nat Commun 14, 342.
- 1371 Miller, K.L., Alfaro-Almagro, F., Bangerter, N.K., Thomas, D.L., Yacoub, E., Xu, J., Bartsch, 1372 A.J., Jbabdi, S., Sotiropoulos, S.N., Andersson, J.L., et al. (2016). Multimodal population 1373 brain imaging in the UK Biobank prospective epidemiological study. Nat Neurosci 19, 1374 1523-1536.
- 1375 Moens, T.G., Da Cruz, S., Neumann, M., Shelkovnikova, T.A., Shneider, N.A., and Van Den 1376 Bosch, L. (2025). Amyotrophic lateral sclerosis caused by FUS mutations: advances with 1377 broad implications. Lancet Neurol 24, 166-178.
- 1378 Munoz-Neira, C., Tedde, A., Coulthard, E., Thai, N.J., and Pennington, C. (2019). Neural 1379 correlates of altered insight in frontotemporal dementia: a systematic review. 1380 Neuroimage Clin 24, 102066.
- Network, B.I.C.C. (2021). A multimodal cell census and atlas of the mammalian primary 1381 1382 motor cortex. Nature 598, 86-102.
- 1383 Neumann, M., Bentmann, E., Dormann, D., Jawaid, A., DeJesus-Hernandez, M., Ansorge, 1384 O., Roeber, S., Kretzschmar, H.A., Munoz, D.G., Kusaka, H., et al. (2011). FET proteins 1385 TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from 1386 amyotrophic lateral sclerosis with FUS mutations. Brain 134, 2595-2609.
- 1387 Paul, D., Islam, S., Manne, R.K., Dinesh, U.S., Malonia, S.K., Maity, B., Boppana, R., 1388 Rapole, S., Shetty, P.K., and Santra, M.K. (2019). F-box protein FBXO16 functions as a 1389 tumor suppressor by attenuating nuclear beta-catenin function. J Pathol 248, 266-279.
- 1390 Petrescu, J., Roque, C.G., Jackson, C.A., Daly, A., Kang, K., Casel, O., Leung, M., Reilly, L., 1391 Eschbach, J., McDade, K., et al. (2025). Differential Cellular Mechanisms Underlie

- 1392 Language and Executive Decline in Amyotrophic Lateral Sclerosis. bioRxiv, 1393
 - 2025.2002.2026.640433.
- 1394 Picchiarelli, G., Demestre, M., Zuko, A., Been, M., Higelin, J., Dieterle, S., Goy, M.A., Mallik, 1395 M., Sellier, C., Scekic-Zahirovic, J., et al. (2019). FUS-mediated regulation of
- 1396 acetylcholine receptor transcription at neuromuscular junctions is compromised in 1397 amyotrophic lateral sclerosis. Nat Neurosci.
- 1398 Pineda, S.S., Lee, H., Ulloa-Navas, M.J., Linville, R.M., Garcia, F.J., Galani, K., Engelberg-1399 Cook, E., Castanedes, M.C., Fitzwalter, B.E., Pregent, L.J., et al. (2024). Single-cell 1400 dissection of the human motor and prefrontal cortices in ALS and FTLD. Cell 187, 1971-1401 1989 e1916.
- 1402 Piol, D., Robberechts, T., and Da Cruz, S. (2023). Lost in local translation: TDP-43 and FUS 1403 in axonal/neuromuscular junction maintenance and dysregulation in amyotrophic lateral 1404 sclerosis. Neuron 111, 1355-1380.
- 1405 Repudi, S., Steinberg, D.J., Elazar, N., Breton, V.L., Aquilino, M.S., Saleem, A., Abu-Swai, 1406 S., Vainshtein, A., Eshed-Eisenbach, Y., Vijayaragavan, B., et al. (2021). Neuronal 1407 deletion of Wwox, associated with WOREE syndrome, causes epilepsy and myelin 1408 defects. Brain 144, 3061-3077.
- 1409 Rifai, O.M., Longden, J., O'Shaughnessy, J., Sewell, M., Pate, J., McDade, K., Daniels, M.J., 1410 Abrahams, S., Chandran, S., McColl, B.W., et al. (2022). Random forest modelling 1411 demonstrates microglial and protein misfolding features to be key phenotypic markers in 1412 C9orf72-ALS. J Pathol 258, 366-381.
- 1413 Rifai, O.M., Waldron, F.M., O'Shaughnessy, J., Read, F.L., Gilodi, M., Pastore, A., Shneider, 1414 N., Tartaglia, G.G., Zacco, E., Spence, H., et al. (2024). Amygdala TDP-43 pathology is 1415 associated with behavioural dysfunction and ferritin accumulation in amyotrophic lateral 1416 sclerosis. bioRxiv.
- 1417 Robinson, J.L., Xie, S.X., Baer, D.R., Suh, E., Van Deerlin, V.M., Loh, N.J., Irwin, D.J., 1418 McMillan, C.T., Wolk, D.A., Chen-Plotkin, A., et al. (2023). Pathological combinations in 1419 neurodegenerative disease are heterogeneous and disease-associated. Brain 146, 1420 2557-2569.
- Rogelj, B., Easton, L.E., Bogu, G.K., Stanton, L.W., Rot, G., Curk, T., Zupan, B., Sugimoto, 1421 1422 Y., Modic, M., Haberman, N., et al. (2012). Widespread binding of FUS along nascent 1423 RNA regulates alternative splicing in the brain. Sci Rep 2, 603.
- 1424 Saez-Atienzar, S., Dalgard, C.L., Ding, J., Chio, A., Alba, C., Hupalo, D.N., Wilkerson, M.D., 1425 Bowser, R., Pioro, E.P., Bedlack, R., et al. (2020). Identification of a pathogenic intronic 1426 KIF5A mutation in an ALS-FTD kindred. Neurology 95, 1015-1018.
- 1427 Sanjuan-Ruiz, I., Govea-Perez, N., McAlonis-Downes, M., Dieterle, S., Megat, S., Dirrig-1428 Grosch, S., Picchiarelli, G., Piol, D., Zhu, Q., Myers, B., et al. (2021). Wild-type FUS 1429 corrects ALS-like disease induced by cytoplasmic mutant FUS through autoregulation. 1430 Mol Neurodegener 16, 61.
- 1431 Scekic-Zahirovic, J., Benetton, C., Brunet, A., Ye, X., Logunov, E., Douchamps, V., Megat, S., Andry, V., Kan, V.W.Y., Stuart-Lopez, G., et al. (2024). Cortical hyperexcitability in 1432 1433 mouse models and patients with amyotrophic lateral sclerosis is linked to noradrenaline 1434 deficiency. Sci Transl Med 16, eadg3665.
- 1435 Scekic-Zahirovic, J., El Oussini, H., Mersmann, S., Drenner, K., Wagner, M., Sun, Y., 1436 Allmeroth, K., Dieterle, S., Sinniger, J., Dirrig-Grosch, S., et al. (2017). Motor neuron 1437 intrinsic and extrinsic mechanisms contribute to the pathogenesis of FUS-associated 1438 amyotrophic lateral sclerosis. Acta Neuropathol (Berl) 133, 887-906.
- 1439 Scekic-Zahirovic, J., Sanjuan-Ruiz, I., Kan, V., Megat, S., De Rossi, P., Dieterle, S., Cassel, 1440 R., Jamet, M., Kessler, P., Wiesner, D., et al. (2021). Cytoplasmic FUS triggers early 1441 behavioral alterations linked to cortical neuronal hyperactivity and inhibitory synaptic
- 1442 defects. Nat Commun 12, 3028.
- 1443 Scekic-Zahirovic, J., Sendscheid, O., El Oussini, H., Jambeau, M., Sun, Y., Mersmann, S., 1444 Wagner, M., Dieterle, S., Sinniger, J., Dirrig-Grosch, S., et al. (2016). Toxic gain of

1445 function from mutant FUS protein is crucial to trigger cell autonomous motor neuron loss. 1446 EMBO J 35, 1077-1097. 1447 Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., 1448 Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012). Fiji: an open-source 1449 platform for biological-image analysis. Nature methods 9, 676-682. 1450 Serchov, T., van Calker, D., and Biber, K. (2016). Sucrose Preference Test to Measure 1451 Anhedonic Behaviour in Mice. Bio-protocol 6, e1958. 1452 Shelkovnikova, T.A., An, H., Skelt, L., Tregoning, J.S., Humphreys, I.R., and Buchman, V.L. 1453 (2019). Antiviral Immune Response as a Trigger of FUS Proteinopathy in Amyotrophic 1454 Lateral Sclerosis. Cell Rep 29, 4496-4508 e4494. 1455 Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., 1456 Green, J., Landray, M., et al. (2015). UK biobank: an open access resource for 1457 identifying the causes of a wide range of complex diseases of middle and old age. PLoS 1458 Med 12, e1001779. 1459 Sun, B.B., Chiou, J., Traylor, M., Benner, C., Hsu, Y.H., Richardson, T.G., Surendran, P., 1460 Mahajan, A., Robins, C., Vasquez-Grinnell, S.G., et al. (2023). Plasma proteomic 1461 associations with genetics and health in the UK Biobank. Nature 622, 329-338. 1462 Sun, L., Cheng, B., Zhou, Y., Fan, Y., Li, W., Qiu, Q., Fang, Y., Xiao, S., Zheng, H., and Li, 1463 X. (2020). ErbB4 Mutation that Decreased NRG1-ErbB4 Signaling Involved in the 1464 Pathogenesis of Amyotrophic Lateral Sclerosis/Frontotemporal Dementia. J Alzheimers 1465 Dis 74, 535-544. 1466 Suzuki, Y., Adachi, T., Yoshida, K., Sakuwa, M., and Hanajima, R. (2024). Psychiatric 1467 symptoms and TDP-43 pathology in amyotrophic lateral sclerosis. J Neurol Sci 466, 1468 123249. 1469 Szewczyk, B., Gunther, R., Japtok, J., Frech, M.J., Naumann, M., Lee, H.O., and Hermann, 1470 A. (2023). FUS ALS neurons activate major stress pathways and reduce translation as 1471 an early protective mechanism against neurodegeneration. Cell Rep 42, 112025. 1472 Tetter, S., Arseni, D., Murzin, A.G., Buhidma, Y., Peak-Chew, S.Y., Garringer, H.J., Newell, 1473 K.L., Vidal, R., Apostolova, L.G., Lashley, T., et al. (2024). TAF15 amyloid filaments in 1474 frontotemporal lobar degeneration. Nature 625, 345-351. 1475 Tyzack, G.E., Luisier, R., Taha, D.M., Neeves, J., Modic, M., Mitchell, J.S., Meyer, I., 1476 Greensmith, L., Newcombe, J., Ule, J., et al. (2019). Widespread FUS mislocalization is 1477 a molecular hallmark of amyotrophic lateral sclerosis. Brain 142, 2572-2580. 1478 Tyzack, G.E., Neeves, J., Crerar, H., Klein, P., Ziff, O., Taha, D.M., Luisier, R., Luscombe, 1479 N.M., and Patani, R. (2021). Aberrant cytoplasmic intron retention is a blueprint for RNA 1480 binding protein mislocalization in VCP-related amyotrophic lateral sclerosis. Brain 144, 1481 1985-1993. 1482 Urwin, H., Josephs, K.A., Rohrer, J.D., Mackenzie, I.R., Neumann, M., Authier, A., Seelaar, 1483 H., Van Swieten, J.C., Brown, J.M., Johannsen, P., et al. (2010). FUS pathology defines 1484 the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta 1485 Neuropathol 120, 33-41. 1486 Van Langenhove, T., van der Zee, J., Sleegers, K., Engelborghs, S., Vandenberghe, R., 1487 Gijselinck, I., Van den Broeck, M., Mattheijssens, M., Peeters, K., De Deyn, P.P., et al. 1488 (2010). Genetic contribution of FUS to frontotemporal lobar degeneration. Neurology 74. 1489 366-371. 1490 Van Nostrand, E.L., Freese, P., Pratt, G.A., Wang, X., Wei, X., Xiao, R., Blue, S.M., Chen, 1491 J.Y., Cody, N.A.L., Dominguez, D., et al. (2020). A large-scale binding and functional 1492 map of human RNA-binding proteins. Nature 583, 711-719. 1493 van Rheenen, W., van der Spek, R.A.A., Bakker, M.K., van Vugt, J., Hop, P.J., Zwamborn, 1494 R.A.J., de Klein, N., Westra, H.J., Bakker, O.B., Deelen, P., et al. (2021). Common and 1495 rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with 1496 distinct genetic architectures and neuron-specific biology. Nat Genet 53, 1636-1648.

- 1497 Vance, C., Rogelj, B., Hortobagyi, T., De Vos, K.J., Nishimura, A.L., Sreedharan, J., Hu, X., 1498 Smith, B., Ruddy, D., Wright, P., et al. (2009). Mutations in FUS, an RNA processing 1499 protein, cause familial amyotrophic lateral sclerosis type 6. Science 323, 1208-1211.
- 1500 Vazquez-Sanchez, S., Tilkin, B., Gasset-Rosa, F., Zhang, S., Piol, D., McAlonis-Downes, M., 1501 Artates, J., Govea-Perez, N., Verresen, Y., Guo, L., et al. (2024). Frontotemporal 1502 dementia-like disease progression elicited by seeded aggregation and spread of FUS. 1503 Mol Neurodegener 19, 46.
- 1504 Wang, Z., Liu, P., Inuzuka, H., and Wei, W. (2014). Roles of F-box proteins in cancer. Nat 1505 Rev Cancer 14, 233-247.
- Yeh, F.C., Vettel, J.M., Singh, A., Poczos, B., Grafton, S.T., Erickson, K.I., Tseng, W.I., and 1506 1507 Verstynen, T.D. (2016). Quantifying Differences and Similarities in Whole-Brain White 1508 Matter Architecture Using Local Connectome Fingerprints. PLoS Comput Biol 12, 1509 e1005203.
- Yeh, F.C., Wedeen, V.J., and Tseng, W.Y. (2010). Generalized g-sampling imaging. IEEE 1510 1511 Trans Med Imaging 29, 1626-1635.
- 1512 Young, P., Qiu, L., Wang, D., Zhao, S., Gross, J., and Feng, G. (2008). Single-neuron
- 1513 labeling with inducible Cre-mediated knockout in transgenic mice. Nat Neurosci 11, 721-1514 728.
- 1515
- 1516

1517 **Figures and legends**



1518 1519 Figure 1: Cross-species transcriptomic analysis identifies FUS-related signature in vulnerable ALS neurons 1520

1521 A. UMAP plot of the 78,514 cells split across 21 clusters identified in the frontal cortex of Fus^{∆NLS/+} mice 1522

- 1523 **B.** UMAP plot of the 156,545 cells split across 19 clusters in the human M1 motor cortex.
- 1524 C. Cluster dendrogram, violin plots heatmaps and histogram plot shows number of genes 1525 detected, percent of each class (Glutamategic, GABAergic and non-neurons), transcriptome-
- wide shift from controls in Fus^{ΔNLS/+} mice and number of DE genes in each cell subclass. 1526
- 1527 **D.** Cluster dendrogram, violin plots, heatmap and histogram bar plot shows number of genes 1528 detected, percent of each class (Glutamategic, GABAergic and non-neurons), transcriptome-1529 wide shift of ALS patients compared to healthy donors and number of DE genes in each cell 1530 subclass.
- 1531 E-F: Intersect plots show the number of DE genes in each excitatory subclass and overlap 1532 used to perform gene ontology analysis in mice and human. Histogram bar plot shows gene
- 1533 ontology terms enriched in all excitatory neurons of ALS patients and Fus^{ΔNLS/+} mice.



1534

1535 Figure 2: Cell-type specific gene module analysis identifies conserved regulatory 1536 networks associated with FUS, and shared with TDP-43.

- A. Experimental design of the gene network analysis in Fus^{ΔNLS/+} mice and ALS patients. 1537
- B. Cluster dendrogam showing the gene modules identified in human ALS patients and 1538 Fus^{∆NLS/+} mice. 1539
- 1540 C-D. UMAP gene network of the selected modules, each dot represents individual gene which
- 1541 size is proportional to its importance (signed kME). The FUS regulon displays a high degree of co-expression in mice which is conserved in ALS patients. 1542
- 1543 E. Bar graphs showing correlation of each module to ALS phenotype and directionality in mice 1544 and human. Dashed lines highlight correlation with FDR<0.05 (Benjamini-Hochberg 1545 correction).
- F. Histogram bar graphs show GO enrichment of the FUS regulon. Dashed lines highlight GO 1546 1547 term with FDR<0.05 (Benjamini-Hochberg correction).
- 1548 **G.** Heatmap shows eigengene of the FUS regulon across all cell types in $Fus^{\Delta NLS/+}$ mice.
- 1549 Wilcoxon rank-sum test with Bonferroni correction *p< 0.05/19 (number of cell types). Dot plot
- 1550 shows FUS regulon eigengene in L5-IT neurons of *Fus*^{ΔNLS/+} mice (Wilcoxon rank-sum test with
- 1551 Bonferroni correction *p=0.00024)
- 1552 H. Heatmap shows FUS regulon eigengene across all cell types in ALS patients. Wilcoxon
- 1553 rank-sum test with Bonferroni correction p < 0.05/21 (number of cell types). Dot plot shows

- 1554 eigengenes expression in L5-PT neurons of Fus^{ΔNLS/+} mice (Wilcoxon rank-sum test with 1555 Bonferroni correction p=0.040)
- 1556 I. Eigengenes expression of the FUS regulon upon downregulation of 217 different RNA-1557 binding proteins and ranked according to effect sizes.
- J. Violin plot showing FUS regulon eigengene expression in iPSC-derived motoneurons 1558 treated with TDP43 shRNA (one-way ANOVA: F_{group} =31.39, **p=0.0025). 1559
- K. Violin plot showing FUS regulon eigengene expression in TDP43⁻ nuclei from FTLD patients 1560
- 1561 (one-way ANOVA: Faroup=21.14, ***p=0.000613).

1563



perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

1565 Figure 3: molecular, histological and electrophysiological consequences of adult

1566 *mislocalization of FUS in cortical projection neurons.*

A. Scheme of the experimental design. Cortical projection neurons show normal nuclear FUS
 until tamoxifen administration (TM) at 6 weeks of age. After this age, FUS is permanently
 mislocalized in the cytoplasm of these neurons, but not in other cell types.

B. Representative immunoblot analysis of FUS protein extracted from the frontal cortex, predicted molecular weights (MW) in kilodalton (kDa) are shown on the left. SOD1, mostly found in the cytoplasm, and HDAC1 exclusively found in the nucleus, were used as control of the purity of extracts. Two antibodies for FUS, targeting either the N-terminal part of FUS or the NLS (in C-terminal) were used.

- 1575 **C.** Quantification of FUS immunoreactive bands in cytoplasmic fractions relative to control mice (two-tailed Mann-Whitney test: *p=0.0127 and **p=0.0013).
- **D.** Representative widefield images of the immunofluorescent staining of cortical neurons in the frontal cortex of 4-month-old mice. GFP and NeuN staining was used to identify neurons (NeuN) recombined (GFP). The FUS antibody used here targets the N-terminal part of FUS, we observed a clear FUS cytoplasmic mislocalization in cortical neurons of Thy1^{CRE-ERT2}/ Fus^{exon15} mice.
- 1582 **E.** FUS regulon eigengene expression in prefrontal cortex of Thy1^{CRE-ERT2}/Fus^{exon15} and control
- 1583 mice 3 months after TM (two-tailed t-test: T=-3.6, *p=0.013.
- 1584 **F.** Scheme of the experimental design for ECoG recording.
- **G.** Assessment of spikes events (defined as an event higher than a window discriminator of 4 times the baseline standard deviation calculated from control mice) at 12 and 20-weeks of age in Thy1^{CRE-ERT2}/ Fus^{exon15} and control mice. Thy1^{CRE-ERT2}/ Fus^{exon15} mice show a number of events two times greater than control mice at 12 weeks (two-tailed Mann-Whitney test; **p=0.0079), and five times greater at 20 weeks two-tailed Mann-Whitney test; **p=0.0079). Cortical activity alteration in transgenic mice significantly increases over time (two-way ANOVA: F_{time} =146.7, p<0.0001) depending on the genotype (two-way ANOVA: F_{genotype}).
- 1592 =455.4, p<0.0001).
- H-K. Neurodegeneration characterization. H. 10 slices per mouse in the frontal cortex or in the motor cortex were selected for counting. I. Representative widefield images of the immunofluorescent staining of cortical neurons in the frontal cortex of 4-month-old mice. NeuN staining was used to identify and count neurons in the upper layers (mainly layer 2-3 and 5).
 J. We highlighted a significant decrease in the number of neurons in the frontal cortex of the transgenic mice (nested t-test: ** p=0.0086) and K. in the motor cortex of those (nested t-test: **p=0.0242).
- 1600

1601Results are expressed as mean \pm SEM, control mice are represented in black and Thy1^{CRE-1602}1602ERT2/ Fus^{exon15} in blue. **C.** Study of FUS mislocalization, n = 6 for control mice and n = 8 for1603Thy1^{CRE-ERT2}/ Fus^{exon15}. **E.** Study of FUS regulon. n = 5 for control mice and n = 5 Thy1^{CRE-ERT2}/1604Fus^{exon15} mice (t-test: *p=0.013). **F.** Study of cortical activity, n = 5 for control mice and n = 51605Thy1^{CRE-ERT2}/ Fus^{exon15} mice. I-K. Study of neurodegeneration, n = 5 for control mice and n = 41606Thy1^{CRE-ERT2}/ Fus^{exon15} mice.

1607 1608



1610 1611 Figure 4: FUS mislocalization in adult neurons leads to ALS-related behavioral and

1612 cognitive impairment.

1613 **A.** Scheme of the experimental design.

B-C. Nesting abilities assessment of Thy1^{CRE-ERT2}/ Fus^{exon15} and control mice. B. Score 1614 1615 attributed to the nests built in a 24hours period starting with 3 g of pressed cotton pieces. We 1616 observed that transgenic mice construct nest that are less complicated that the one performed 1617 by control mice (two-tailed Mann-Whitney test: *p=0.030). C. Mass of pressed cotton pieces 1618 which were found untorn after 24h. The mass of untorn cotton pieces was significantly higher 1619 for Thy1^{CRE-ERT2}/ Fus^{exon15} than for control mice (two-tailed Mann-Whitney test: *p=0.045), 1620 highlighting difficulties to plan and/or execute the successive steps involved in nesting.

1621 **D-F** Sociability and social memory assessed using 3 chamber test. **D** During the first 3 trials, 1622 we measured the time spent contacting an empty cage or a cage with a mouse (mouse) while 1623 during the fourth trial, an unknown mouse is introduced (novel mouse) and allowed to assess 1624 the innate attractivity of mouse for novelty. Three-way ANOVA analysis showed a decrease of 1625 interest over time (F_{time} =8.217, p=0.0008), a higher interest for the mouse than the empty box 1626 (F_{boxes} = 157.6, #p<0.0001) and a difference between genotype (F_{genotype} = 4.075, *p=0.0488). **E**. 1627 Social memory evaluation by presenting a mouse already met (during trial 1-3, i.e. Known mouse) and a novel mouse. The contacting time of Thy1^{CRE-ERT2}/Fus^{exon15} mice with novel mice 1628 1629 was significantly lower compared to those of control mice (two-way ANOVA: Fgenotype=14.39, 1630 ***p=0.0006). Sidak's multiple comparisons test indicated significant higher exploration of

- 1631 novel mice in comparison to the known one in control mice (### p<0.0001). This is not the 1632 case for Thy1^{CRE-ERT2}/ Fus^{exon15} mice (p=0.8783). F. The recognition index, computed as the 1633 contacting time with novel mouse divided by the total contacting time, was significantly 1634 decreased compared to those of control mice (two-tailed Mann-Whitney test: *p=0.035). When 1635 we compared this recognition index to chance level (placed at 50 and indicated by the 1636 horizontal dotted line), we observed that only control mice presented an index higher than chance level (one sample t-test: control mice \$p<0.0001 and Thy1^{CRE-ERT2}/ Fus^{exon15}. 1637 1638 p=0.2233).
- **G-H.** Social alteration assessed in another paradigm, resident intruder test. We placed in the tested mouse cage an intruder and assess for 5 min the total contacting time (**G**) and the total number of contact (**H**). We confirmed the social alteration observed in Thy1^{CRE-ERT2}/ Fus^{exon15} as they spent less time contacting the intruder than the control mice (two-tailed Mann-Whitney
- test: *p=0.0317) and showed a lower number of total interactions (two-tailed Mann-Whitney test: **p=0.0011).
- I-J. Short-term (10 min) and long term (24hours) object recognition memory. I. We did not observe any short-term object memory alteration (two-tailed Mann-Whitney test: p=0.662).
 Both groups spent more time than chance level (indicated by the horizontal dotted line) exploring the novel object (one sample t-test: \$p=0.011 for control mice and \$\$p=0.0058 for Thy1^{CRE-ERT2}/ Fus^{exon15} mice). J. Long-term (10 min) object recognition memory is not affected either (two-tailed Mann-Whitney test: p=0.345). Both groups spend more time than chance level exploring the new object (\$p=0.016 for control mice and \$\$\$p=0.0005 for Thy1^{CRE-ERT2}/
- 1652 Fus^{exon15} mice).
- 1653

1654Results are expressed as mean \pm SEM, control mice are represented in black and Thy1^{CRE-1655}1655ERT2/ Fus^{exon15} in blue. **D-F**. Study of 3 sociability in 3 chamber test, n = 9 for control mice and1656n= 10 for Thy1^{CRE-ERT2}/ Fus^{exon15} mice. **G-H** Study of sociability in resident intruder test, n= 12

- 1657 control mice and n = 11 for Thy1^{CRE-ERT2}/ Fus^{exon15} mice. **I-J** Study of object recognition, n = 6
- 1658 control mice and n = 8 for Thy1^{CRE-ERT2}/ Fus^{exon15} mice.
- 1659



1660

1661Figure 5: FUS mislocalization and downregulation of FUS regulon in vulnerable neurons1662of patients with ALS and cognitive impairment

1663 A. Representative photomicrographs of C9ORF72 human post-mortem tissue taken at 10x 1664 (top panel) and 40x magnification with optical zoom (middle and lower panels) demonstrating 1665 DAB immunohistochemical staining for FUS protein in BA39 (language brain region). These 1666 cases had undergone ECAS testing during life, evaluating language function of this brain 1667 region, and based on clinically approved cut offs cases were classified as affected (ECAS 1668 score < or = 26) or unaffected (ECAS score > 26). Black arrowheads indicate nuclear 1669 pathology, and white arrowheads indicate cytoplasmic pathology within layers III and V of the 1670 cortex.

B-C. Cell counts were performed by counting the number of cells affected by cytoplasmic pathology (B) or nuclear pathology (C) in 10 randomly assigned regions of interest (1.5 mm2) in three cases for each group. Cell counts were performed by a pathologist who was blinded to case and demographic data. ALS cases with normal language function are plotted in yellow and with language dysfunction plotted in red. Each case is plotted demonstrating the variability between and within cases.

1677 **D.** Heatmap showing cell-type specific expression of L5-ET marker genes in 9 excitatory 1678 neuron subclasses spanning four different tissues (BA4,BA9,BA44 and BA46).

1679 E. Uniform manifold approximation and projection (UMAP) UMAP plot projecting gene
 1680 expression from 287,275 excitatory neurons colored by subclasses and density plot showing
 1681 the expression profile of L5-ET top marker genes (*ADRA1A,POU3F1,VAT1L* and *SULF2*) in

- 1682 L5-ET subgroups and L5-ET subtypes top marker genes (NETO1, SERPINE2, THSD4 and 1683 GRIN3A)
- 1684 F. UMAP plot colored by sampled tissue show selective regional presence of L5-ET subgroups 1685 across motor areas (BA4) and prefrontal area of the cortex (BA9, BA44, BA46).
- 1686 **E.** UMAP plot split according to diagnosis show a reduction in L5-ET neurons.
- 1687 **H.** Bar plot showing proportion of each excitatory neurons subclass sampled across all donors 1688 and showing a reduction in L5-ET neurons in ALSci patients compared to ALS and HC (inset 1689 on the right). The lower panel shows results of a permutation-based test identifying L5-ET 1690 neurons as significantly depleted in ALSci patients (FDR<0.05 & log2 Fold difference <-0.58).
- 1691 I. Heatmap displays FUS regulon expression across major subclasses of excitatory neurons
- 1692 in controls (HC), ALS and ALSci patients. A significant decrease is observed in L5-ET neurons 1693 in ALSci compared to controls (Wilcoxon rank sum test Bonferroni adjusted **p=0.007) and in
- 1694 ALS compared to ALSci patients (Wilcoxon rank sum test Bonferroni adjusted **p=0.044). 1695 *Adjusted-p <0.05 vs HC, # Adjusted-p <0.05 vs ALS. The violin plot on the right shows FUS 1696 regulon expression difference in L5-ET neurons of ALSci compared to controls (Wilcoxon rank
- 1697 sum test Bonferroni adjusted **p=0.002) and ALS (Wilcoxon rank sum test Bonferroni adjusted
- 1698 *p=0.029) but not between ALS and HC (Wilcoxon rank sum test Bonferroni adjusted p=0.051).
- 1699 J. Unsupervised clustering of ALS donors (n=36) screened for cognitive impairment shows a
- 1700 clear separation between ALS patients (n=22) and ALSci patients (n=14) and heterogeneity in
- 1701 clinical scores. Heatmap displays clinical score across 4 ECAS domains that are ALS specific 1702 (Executive,Language and Verbal Fluency) and non-specific (Memory). Overlay heatmaps
- 1703 show FUS regulon expression across donors, TDP43 burden, disease duration and genetic
- 1704 burden of rare and common variants associated with neurodegenerative disease-associated 1705 dementia.
- 1706 K. Scatter plot shows FUS regular expression correlation with clinical ALS specific score (R2=0.32,p=0.051) and ECAS total score (R2=0.326,*p=0.048). 1707
- 1708 L. Corrplot displays strong correlation across clinical subscore across individuals and a 1709 significant correlation of the FUS regulon expression with executive function in BA46 1710 (R2=0.60,*p=0.017) but not with language in BA44 (R2=0.37,p=0.26) illustrated in scatter plots 1711 on the right.
- 1712 **M.** Strategy to relate genetic burden of dementia to FUS regulon expression and cognitive 1713 impairment.
- N. Violin plot shows a significant reduction of the ECAS total score in ALS patient with high 1714 1715 genetic burden (>=2 screened missense variants per patient) vs low (< 2 screened missense
- 1716 variants per patient) (Wilcoxon rank sum test *p=0.034).
- O. Dot plots across patients colored by diagnosis shows an increase burden of the number of 1717 1718 genetic variation observed per individual in known genes and its association with clinical 1719 subscores.
- 1720 P. Scatter plot shows FUS regular expression inverse correlation with genetic burden across
- 1721 donor (R2=-0.39,*p=0.034).
- 1722





1723 1724

Figure 6: FUS regulon is enriched in ALS/FTD heritability and prioritizes FBX016 as a 1725 novel risk factor for ALS associated with behavioral impairment.

1726 A. Strategy to characterize heritability through integration of GWAS with the FUS regulon.

1727 Each gene in the FUS regulon was mapped to the associated TSS and/or enhancer through 1728 single nuclei ATACseq (snATACseq) and linkage disequilibrium score regression computed 1729 as described previously

- 1730 **B.** Dots indicate enrichment and 95% confidence interval computed from LD-score regression. 1731 Two-sided p-values were derived from linear regression in LDSC analysis. * Indicates 1732 significance after Bonferroni correction p<0.05/12. Results indicate enrichment for ALS-GWAS
- 1733 *p=1.07.10⁻²⁴ and the FUS regulon *p=1.3.10⁻⁹ in ALS heritability but no significant enrichment 1734 for randomly samples set of genes (p>0.05).
- C. Genetic risk factors for ALS, ALS-FTD and FTD were overlapped with the FUS regulon. 1735 1736 Venn diagram show overlap between each group with a significant overlap between ALS-FTD 1737 gene and FUS regulon (Fisher's exact test p=2.2.10⁻⁰⁶) but not with ALS only (Fisher's exact 1738 test p=0.054) or FTD only (Fisher's exact test p=0.33).
- D. Strategy to perform GWAS of ALS associated with cognitive (ALS-ci) or behavioral 1739 1740 impairment (ALS-bi). Whole genomic sequencing from ALS patients were filtered for SNPs with minor allele frequency above 5% (MAF > 0.05). WGS were then filtered based on gene 1741 1742 overlap with FUS regulon genes leading to 131,202 SNPs used for GWAS.
- 1743 E. Quantile–Quantile plot depicting on x-axis the -log10 of expected p value versus the 1744 actually measured p values from generalized logistic regression for 131,202 SNPs association 1745 with ALS-ci. Genome-wide correction for multiple testing was set at P<1×10⁻⁶. Highlighted 1746 SNP in red reaches genome-wide significant (p=5.44.10⁻⁰⁷) and is located in the FBXO16 gene. 1747 F. Quantile–Quantile plot depicting on x-axis the -log 10 of expected p value versus the
- 1748 actually measured p values from generalized logistic regression for 131,202 SNPs association

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

1749 with ALS-bi. Genome-wide correction for multiple testing was set at $P < 1 \times 10^{-6}$. Highlighted 1750 SNP in red reaches suggestive significance (p=5.08.10⁻⁰⁵) and located in WWOX gene.

1751 G. Forest plot display per-GWAS association of rs11991627 (FBXO16) and rs12324967 1752 (WWOX) in ALS-ci and ALS-bi. Odds ratio (OR) values and 95% CI for each cohort are 1753 depicted in different color. The graphs display the means and 95% confidence interval.

1754 H. Locus zoom plot showing the SNP (+/- 500KB) rs11991627 (FBXO16) association with

1755 ALS-bi. Red dashed lines show the genome-wide significant SNP at a p-value < 6.10⁻⁰⁷ and

- 1756 colored dots represent LD with the lead variant (red diamond). I. Violin plots shows behavioral
- 1757 score in rs11991627 carriers of homozygous reference allele (n=139) compared to 1758
- heterozygous carriers (n=104) (One-way ANOVA Fgenotype=14.26, p=1.31.10⁻⁰⁶, Tukey's posthoc $**p=2.58.10^{-03}$) and to homozygous carriers (n=25) (Tukey's post-hoc $****p=5.67.10^{-06}$). 1759
- 1760
- 1761





1764 Figure 7: FBXO16 PTV carriers have behavioral deficits associated with fronto-temporal 1765 atrophy and increase plasmatic expression of NEFL and GFAP.

1766 A Strategy to characterize FBXO16 PTV carriers in the UK Biobank, and numbers of 1767 individuals included. FBXO16 PTV carriers (n=231) were screened for symptoms associated 1768 with cognitive or behavioral deficits among 460,312 individuals of European ancestry. We then 1769 evaluated alteration of the brain structure using diffusion and T1 structural MRI from FBXO16 1770 PTV carriers (n=13) and 37,817 non-carriers controls individuals. Finally, we have used large-1771 scale proteomics data from the UK-Biobank to test whether FBXO16 PTV carriers (n=14) show 1772 significant alteration in major biomarkers when compared to age and sex-matched controls 1773 (n=21.604). Levels of different proteins were compared to incident diseased cases diagnosed 1774 with Alzheimer's dementia (n=642), ALS (n=198), FTD (n=70) and Vascular dementia (n=161). 1775 **B.** Logistic regression analysis testing whether *FBXO16* PTV carriers' status predict UK-1776 Biobank associated symptoms and signs involving cognition, perception, emotional states and

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

behavior. Forest plot shows significant association of *FBXO16* genotype with R45 category (Logistic regression Beta coefficient = 1.22; (0.81-1.64), *p=0.0030). *Significance is set at pvalues < 0.05 / 6. A significant association is observed between *FBXO16* genotype and two R45 subcategory which are hostility (Beta coefficient = 2.92, (1.91-3.92), *p=0.0037) and nervousness (Beta coefficient = 2.76, (1.75-3.77), *p=0.006) and a suggestive association with apathic behavior (Beta coefficient = 0.80, (0.46-1.14), p=0.018). *Significance is set at Bonferroni corrected p-value < 0.05 / 6 = 0.008.

C. Heatmap depicts -log10(p) obtained from generalized linear model testing whether FBXO16 genotype is a predictor of IDPs obtained from diffusion MRI imaging of FBXO16 carriers (n=13) and non-carriers (n=37,817). GLM p-values are depicted for the fractional anisotropy and axial diffusivity for both hemispheres and each of the white matter tracts. A significant association is observed between FBXO16 genotype and a decrease FA of the genu of the corpus callosum (Beta = -0.03 (-0.048,-0.012),* adjusted-p =0.041) and a decrease AD of the left uncinate fasciculus (Beta coefficient = -6.17.10⁻⁰⁵ (-9.53.10⁻⁰⁵, -2.8.10⁻⁰⁵), *adjusted-p=0.337).

1791 D-F. Heatmap shows the percentage of each of the 31 structures from the Desikan-Killiany 1792 cortical parcellation atlas which is connected to the nine major white matter tracts in FBXO16 1793 PTV carriers and non-carriers. We observe a decrease in the percentage of the structure 1794 connected through the left uncinate fasciculus to the pars orbitalis (BA47), the pars-triangularis 1795 (BA45) and the rostral-middle frontal (BA46). Dashed rectangles. The number of tracts from 1796 the left uncinate fasciculus connecting to BA47. BA45 and BA46 is significantly decreased in 1797 FBXO16 carriers compared to non-carriers (unpaired t-test: t=2.16, *p=0.045). Also, we 1798 observed a lower proportion of highly connected tracts of the uncinate fasciculus to BA44, 1799 BA45, and BA47 in FBXO16 PTV carriers when compared to non-carriers (Fischer's exact test: 1800 X-squared = 4.576, df = 1, *p = 0.032).

G. Illustration shows the Z-score differential gray matter area and volume. Unbiased brainwide cluster correlation analysis reveals a significant decrease in left gray matter area located on the frontal region in the pars triangularis (BA45) and the rostral medial frontal region (BA46). Region-of-interest reveals a significant decrease in the left pars triangularis gray matter area (unpaired-t test: t=3.24, **p=0.0047) and volume (unpaired-t test: t=3.33, **p=0.0036).

1806 **H.** Volcano plot shows a significant association between increase GFAP (Beta coefficient = 1807 0.332, adjusted-p=3.25.10⁻⁰⁵) and NEFL (Beta coefficient = 0.337, adjusted-p=1.96.10⁻⁰⁶) 1808 protein levels in the plasma with incidence of FTD. Forest plot display association between 1809 GFAP and NEFL levels with dementia subtypes which significant for Alzheimer's disease (GFAP-Beta coefficient = 0.29, ***p=3.38.10⁻⁴⁹; NEFL- Beta coefficient = 0.17, ***p=1.08.10⁻¹⁹; 1810 1811 ²³), vascular dementia (GFAP-Beta coefficient = 0.22, ***p=5.45.10⁻⁰⁶; NEFL- Beta coefficient 1812 = 0.16, ***p=8.32.10⁻⁰⁴). Only a significant association of NEFL with ALS (NEFL- Beta 1813 coefficient = 0.14, **p= $3.17.10^{-03}$) but not with GFAP (NEFL- Beta coefficient = -0.003, p=0.92) 1814 In FBXO16 carriers a significant association is observed for NEFL (NEFL- Beta coefficient = 1815 0.27, **p=0.0047) and trend for GFAP (GFAP- Beta coefficient = 0.19, p=0.085). Violin plot 1816 show a significant increase in mean GFAP protein expression (D-cohen = 0.47; one-tailed 1817 *permuted-p = 0.027) and NEFL (D-cohen = 0.67; one-tailed **permuted-p = 0.0023) in 1818 FBXO16 PTV carriers.